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SUMMARY 
Tuberculosis (TB) is an epidemic disease characterised by wet, persistent coughing, weight 
loss, fever, fatigue, and blood in the sputum. It has been reported that one in every three 
individuals is currently infected with Mycobacterium tuberculosis, the causative agent of TB, 
and that 10% of them will develop the active disease. The high prevalence and low 
penetrance of this disease has resulted in increased research performed to ascertain what 
factors play a role in susceptibility to M. tuberculosis infection. Some factors known to play a 
role in a minority of cases may include: HIV infection, diabetes, alcohol abuse and old age, 
but racial differences in susceptibility have also been observed. However, the influence of 
genetic factors is gaining popularity in current research. 
M. tuberculosis requires iron to proliferate, which it must appropriate from its host. For this 
reason the genes involved in the metabolism of iron in the human host are of particular 
interest when considering susceptibility to M. tuberculosis infection. In order to determine 
whether the expression of these genes may influence disease susceptibility, the promoter 
region of the CYBRD1, HAMP, HFE, LTF and SLC40A1 genes have been targeted for 
investigation. The aim of this study was to determine whether DNA variation in the promoter 
region of these genes involved in iron metabolism is associated with M. tuberculosis 
susceptibility. 
The study cohort consisted of 49 TB patients and 51 healthy, unrelated, population-matched 
controls, all of whom were Black, Xhosa-speaking individuals. Initially, 15 patient samples 
were randomly selected for exploratory screening, utilising semi-automated bi-directional 
sequencing analysis. In this manner, 40 variants were identified of which 30 were previously 
described. The novel variants included CYBRD1: -849 C/G, -492 A/G, -454 C/T, -397 A/C; 
HAMP: -323 C/T; HFE: -561 A/G, -331 A/C; and LTF: -1377 T/G, -457 T/C, -437 C/G. A 
number of loci demonstrated a statistically significant difference in allele and genotype 
frequencies, and in iron parameter levels when comparing the patient and control groups and 
for each variant separately. In silico analyses revealed the creation and/or abolishment of 
several transcription factor binding sites (TFBSs) due to the presence or absence of certain 
identified variants. The change in the composition of TFBSs in the promoter region may lead 
to differential expression of the gene. 
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This study served as a pilot investigation to identify promoter region variants in the candidate 
genes involved in iron metabolism, in TB patients. The results presented here indicate that the 
identified variants (-1813 C/T, -1459 T/C, -238 A/G, -166 C/G [CYBRD1]; -561 A/G [HFE]; 
-1470 C/T, -1355 G/C and -1098 G/A [SLC40A1]) could possibly contribute to the increased 
absorption of iron in the TB patient group, which could subsequently increase the occurrence 
of pathogenic infection. The findings of this study could further aid in the elucidation of the 
exact mechanism(s) by which iron, its metabolism, and the genes involved affect disease 
susceptibility, more specifically, M. tuberculosis susceptibility. 
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OPSOMMING 
Tuberkulose (TB) is „n epidemiese siekte gekarakteriseer deur nat, aanhoudende hoes, 
gewigsverlies, moegheid, en bloed in die speeksel. Dit is gerapporteer dat een in elke drie 
individue tans geïnfekteer is met Mycobacterium tuberculosis, die veroorsakende agent van 
TB, en dat 10% van dié individue die aktiewe vorm van die siekte sal ontwikkel. Die hoë 
voorkoms en lae effek van hierdie siekte het daartoe gelei dat meer navorsing mettertyd 
gedoen is om die faktore wat „n rol mag speel in M. tuberculosis infeksie, te bepaal. 
Sommige faktore bekend vir hul rol in „n minderheid van gevalle sluit in: MIV infeksie, 
diabetes, alkoholmisbruik en bejaardheid, maar etniese verskille in vatbaarheid vir die siekte 
is ook al waargeneem. Die waarskynlikheid van genetiese invloed op die ontwikkeling van 
TB word ook meer deur navorsers ondersoek. 
M. tuberculosis benodig yster om te vermeerder, wat dit moet bekom vanaf die gasheer. Vir 
hierdie rede is die gene betrokke by yster metabolisme in die menslike gasheer veral van 
belang vir die oorweging van vatbaarheid vir M. tuberculosis. Om te bepaal of die 
uitdrukking van hierdie gene moontlik „n invloed het op vatbaarheid vir die siekte, was die 
promoter areas van die CYBRD1, HAMP, HFE, LTF en SLC40A1 gene geteiken. Die doel 
van hierdie studie was om te bepaal of DNS variasie in die promoter area van hierdie gene 
betrokke in yster metabolisme moontlik verband kan hou met vatbaarheid vir M. tuberculosis. 
Die studie kohort het uit 49 TB pasiënte en 51 gesonde, onverwante, populasie-gepaarde 
kontroles, waarvan almal Swart, Xhosa-sprekende individue was, bestaan. Aanvanklik was 
15 pasiënt monsters lukraak gekies vir ondersoekende sifting, deur die gebruik van semi-
outomatiese twee-rigting volgordebepalings. Op hierdie manier is 40 variante geïdentifiseer 
waarvan 30 voorheen beskryf is. Die nuwe variante sluit in CYBRD1: -849 C/G, -492 A/G, -
454 C/T, -397 A/C; HAMP: -323 C/T; HFE: -561 A/G, -331 A/C; en LTF: -1377 T/G, -457 
T/C, -437 C/G. „n Aantal loci het statisties betekenisvolle verskille getoon in alleel en 
genotipe frekwensies, en in yster parameter vlakke met die vergelyking van die pasiënt groep 
met die kontrole groep. In silico analise het verder die skepping en/of afskaffing van verskeie 
transkripsiefaktor bindingsetels (TFBSs), as gevolg van die teenwoordigheid of afwesigheid 
van sekere variante, getoon. Die verandering in die samestelling van TFBSs in die promoter 
area kan lei tot differensiële uitdrukking van die geen. 
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Dié studie het gedien as „n voorlopige ondersoek om te bepaal of promoter area variante, 
geïdentifiseer in kandidaat gene betrokke by yster metabolisme, „n invloed het in die 
ontwikkeling van TB. Die resultate wat hier gewys word dui aan dat die geïdentifiseerde 
variante (-1813 C/T, -1459 T/C, -238 A/G, -166 C/G [CYBRD1]; -561 A/G [HFE]; -1470 
C/T, -1355 G/C and -1098 G/A [SLC40A1]) moontlik die verhoogde opname van yster kan 
veroorsaak, wat later die toename van die patogeniese infeksie kan veroorsaak. Die 
bevindinge van hierdie studie kan moontlik bydra tot die toeligting van die presiese 
meganisme(s) waardeur yster, yster metabolisme, en die betrokke gene vatbaarheid vir siekte, 
meer spesifiek M. tuberculosis vatbaarheid, beïnvloed. 
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1. LITERATURE REVIEW 
1.1 TUBERCULOSIS  
Tuberculosis (TB) is an infectious disease affecting, and taking, the lives of many people 
worldwide. TB can affect almost all parts of the body but the most common site of infection 
is the lungs. The general symptoms include fever, night sweats, a wet and persistent cough 
occasionally accompanied by blood in the sputum, weight-loss, and fatigue (Perez-Osorio et 
al., 2012). 
It has been postulated that this disease has existed for approximately 15 000 to 20 000 years 
but the oldest evidence of TB infection in humans has been found in bone fossils which date 
back to 8 000 BCE (Herzog, 1998). Further research suggests that 25 of the world‟s major 
diseases caused by pathogens, of which TB is one, originated in what is known as the Old 
World (Africa, Asia and Europe) (Wolfe et al., 2007). The exact date of the first human 
infection with TB is unclear and molecular methods to genetically determine this are 
inadequate as they only take into account the genetic information for the current strains of the 
infectious pathogen (Smith et al., 2009). These methods do not take into account strains that 
no longer exist, from which current strains may have originated; the genetic information from 
the original ancestor is important as it could provide resolution as to the changes to the 
genome which facilitated human infection. The discovery of the precise origin of this 
pathogen-derived disease, both geographical and temporal, and the determination of its 
lineage, could provide insight in terms of control, treatment and eradication. 
TB is mainly found in temperate regions and is considered to be a “crowd epidemic disease” 
which is defined as “occurring locally as a brief epidemic and capable of persisting regionally 
only in large human populations” (Wolfe et al., 2007). In present times, a decreased number 
of infections is observed in the Caucasian population group when compared to other ethnic 
groups, such as the Sub-Saharan Africans. This could be explained by prolonged exposure to 
TB during times of industrialization, from the seventeenth century onwards, when regions 
such as Europe and North America experienced population booms and TB epidemics were 
common (Lipsitch & Sousa, 2002). The prolonged exposure of these Caucasians to the 
disease may have exerted a selective pressure on this ethnic group to select for resistant 
individuals. This is supported by Fares (2012) in a review article which reports that Black 
individuals have a higher prevalence of TB infection when compared to Caucasians. 
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The basis for this racial difference in susceptibility to TB is as yet unclear but socio-
economic, immunologic, environmental and genetic factors have been implicated (Fares, 
2012).  
The following sub-sections will expound on the disease and will present information 
regarding the prevalence, aetiology, diagnosis, and treatment thereof. 
 
1.1.1 Disease Penetrance and Prevalence 
The African continent was ranked as the second highest contributor to the world‟s TB burden 
in 2010, contributing 26% of TB cases worldwide (WHO, 2011). For the year 2012, the 
World Health Organisation (WHO) reported that South Africa had approximately 390 000 
reported cases of active TB and close to 25 000 patients succumbed to the disease (WHO, 
2012). According to this report, South Africa also has the highest number of TB cases co-
infected with HIV when compared to other countries worldwide. The high prevalence of TB 
cases in this country is surprising when one considers the low penetrance of this disease: it 
has been estimated that at least one in every three individuals in the world is infected with the 
bacterium that causes TB but that only 5 to 10% of these cases will present with active TB 
(Dye et al., 1999; Herzog, 1998). The high prevalence of this low penetrating disease could 
be attributed to a number of factors influencing susceptibility. Some of these factors 
including environment, socio-economic status and immunology, could explain why South 
Africa contributes such a large proportion to the world‟s TB burden but genetics has 
specifically been implicated as playing a role in susceptibility to TB among Africans 
(Bellamy et al., 2000). There is much support for a genetic influence on susceptibility to TB: 
one of the best examples for this support comes from twin studies (Lipsitch & Sousa, 2002). 
Monozygotic twins have been shown to have a higher level of concordance in TB morbidity 
than dizygotic twins, and this concordance decreased as the blood relationship distance 
increased (Comstock, 1978).  
 
1.1.2 The Causative Agent – Mycobacterium tuberculosis  
Mycobacterium tuberculosis (M. tuberculosis) is the aetiological agent of most forms of TB. 
Since its discovery in 1882 by Robert Koch, much research has been done on the bacterium 
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and the causative disease. The full genome sequence was determined in 1998 and was shown 
to be 4 411 529 base pairs (bp) in length containing approximately 4 000 genes (Cole et al., 
1998; Camus et al., 2002). This bacterium is a rod-shaped, gram-positive, acid-fast obligate 
aerobe which is non-motile. The bacterium‟s genome is GC-rich and it has a dividing time of 
approximately 24 hours which sets it apart from most other pathogenic bacteria which can 
divide in less than one hour (Cole et al., 1998). The cell wall of M. tuberculosis contains high 
levels of lipids and mycolic acid, which only weakly retains crystal violet dye, if at all; thus, 
from an empirical stand-point, it is not technically gram-positive. It is classified as such 
because, like other gram-positive bacteria, it does not have an outer cell membrane 
(Gregersen, 1978). The bacterium can withstand dilute disinfectants and has the ability to 
survive in a dry state for several weeks, which is most likely due to its unique cell wall 
contents (Madison, 2001). 
The bacterium most commonly infects the lungs; consequently transmission from an infected 
individual to a healthy, uninfected individual relies on the aerosolization of the bacteria. 
(Dillon et al., 2000; Nicas et al., 2005). It is important to note that only people with active 
TB, who have developed symptoms due to the bacteria escaping the confinement of a 
granuloma, are contagious, whereas passive TB patients, who have not developed any active 
symptoms, are considered unable to transmit the bacteria to other healthy individuals (Kumar 
et al., 2007).  
 
1.1.2.1 Diagnosis 
There are many methods for the diagnosis of TB but the method used most often relies on the 
socio-economic status of the country where tested (Metcalfe et al., 2011). Figure 1.1 
illustrates the most common methods of testing for M. tuberculosis infection.  
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Figure 1.1 The most common testing methods for the diagnosis of M. tuberculosis infection. Testing begins when a patient 
displays TB symptoms following which a sputum or biopsy sample may be collected for testing. The most popular tests used 
include sputum culturing, acid-fast staining and PCR-based methods. 
 
If M. tuberculosis infection is suspected (the patient displays all the symptoms and is at high 
risk for infection) then a sputum sample or tissue biopsy may be taken for analysis. 
Fluorescence microscopy may be performed on the sample in order to determine the 
morphology of any infecting bacteria present using an acid-fast fluorochrome dye, such as 
auramine-O, to determine whether it is a bacillus infection. Fluorescence microscopy is an 
expensive method to use for testing and often in low- to middle-income countries 
conventional light microscopy using the Ziehl-Neelsen acid-fast stain is used. However, 
conventional light microscopy has been shown to be less sensitive than fluorescence 
microscopy. 
The sample may also be sent to be cultured on selective medium but as the bacterium has a 
slow generation time the culture period may take as long as 6 to 8 weeks (Wilson et al., 
1997). In developed countries where funding is more readily available, polymerase chain 
reaction (PCR) based techniques are being used to identify whether a patient is infected with 
M. tuberculosis and kits for these purposes have been available since the 1990s, although 
sputum culture still remains the primary technique performed to verify M. tuberculosis 
infection (Causse et al., 2011). 
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In some instances a tuberculin skin test can be performed to test for infection. The most 
commonly used tuberculin skin test is the Mantoux test (Rothel & Andersen, 2005). This test 
involves the injection of the tuberculin antigen into the flexor surface of the forearm where a 
reaction will occur with the antibodies formed by someone infected with M. tuberculosis 
(Huebner et al., 1993). The site of injection will show a delayed-type hypersensitivity 
response. This response reaction needs to be larger than a certain diameter before a positive 
result can be established. 
Vaccines have been developed for the prevention of TB infection and the most widely used is 
the bacillus Calmette-Guerin (BCG) vaccine (Rothel & Andersen, 2005). This vaccine is 
intended to prevent infection by bacillus bacteria and is administered to people in regions of 
high risk for infection. In developing countries most of the population receives the BCG 
vaccine which causes the formation of antibodies which may interfere with the Mantoux test, 
where a false-positive might be observed. For this reason the Mantoux test is not generally 
used in developing countries. 
In developed countries, however, the BCG vaccine is not commonly administered unless the 
individual is at high risk of infection. The Mantoux test is more commonly performed in 
these regions (Teo & Shingadia, 2006). Interferon-γ release assays (IGRAs) are assays that 
measure the release of interferon-γ which is secreted by the body in response to inflammation 
and infection, and so can also be used to show infection by M. tuberculosis. It too may 
present false-positive results and cannot distinguish between latent, active or past infection 
with M. tuberculosis (Sester et al., 2011). Chest x-rays are sometimes performed on patients 
with a chronic cough but, although the x-ray may show regions of granulomatous tissue, they 
are not specific enough to confirm tuberculosis and will rather aid in the determination of the 
patient‟s prognosis (Herzog, 1998). 
 
1.1.2.2 Disease Progression and Treatment 
As mentioned previously, the bacterium can be contracted from airborne, aerosolised 
particles produced by infected individuals. Once these particles are inhaled and enter the 
alveoli they have access to their primary site of infection, which are reticuloendothelial 
macrophages (Wagner et al., 2005). Infection is initiated when mycobacteria enter the 
endosome of the macrophage, where they can grow and divide without the probability of 
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fusing with lysosomes and being digested. The exact mechanism by which the bacterium 
escapes the fusion of the endosome to the lysosome is poorly understood. The host system 
responds by encasing the invading pathogen with varying types of white blood cells forming 
a granuloma (Saunders & Britton, 2007). On the periphery of a granuloma are T cells, 
macrophages (both infected and uninfected), foamy giant cells and, at the centre, a firm 
caseous core (Stewart et al., 2003). The entire granuloma or tubercle is isolated from the 
surrounding tissue by a fibrotic capsule. This asymptomatic stage is known as latent 
infection. Once the infectious bacteria overwhelm the immune system‟s defences, the 
granuloma will perforate and allow for the bacteria to spread and symptoms will begin to 
appear. This stage is termed active infection. 
The treatment regimen for TB is personalised for each patient but Figure 1.2 illustrates a 
general strategy for the treatment of both drug-susceptible and drug-resistant TB. 
 
 
Figure 1.2 Standard and drug-resistant TB treatment regimens. Standard, non-drug-resistant TB treatment comprises of a 6 
month period where a combination of at least 6 antibiotics are used. In contrast, drug-resistant TB treatment may last as long 
as 2 years involving multiple antibiotic treatments in varying stages. 
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First-line drugs are used for a period of six months for cases of drug-susceptible TB 
(Caminero et al., 2010). M. tuberculosis is considered to be constantly mutating and has 
gained resistance to many antibiotics which impedes attempts to eradicate the disease. With 
the increasing incidence of drug-resistant M. tuberculosis being seen in Europe, Asia and 
sub-Saharan Africa new treatment regimens have been developed (Lawn & Zumla, 2011). 
The exact combination of drugs used is dependent on the patient‟s history of previous M. 
tuberculosis infection, adherence to previous regimens and other factors. In most cases of 
drug-resistant TB, secondary anti-tuberculosis drugs, such as fluoroquinolones, need to be 
incorporated (Caminero et al., 2010). 
 
1.2 IRON AND TUBERCULOSIS – ADAPTATION TO HUMAN INFECTION 
Iron is a vital element required for the proliferation of M. tuberculosis. For example, iron is 
an obligate co-factor for 40 different enzymes encoded by the genome of M. tuberculosis 
(Cole et al., 1998). Since M. tuberculosis cannot produce iron it must sequester this essential 
element from its host. Over time the bacterium has developed methods for outcompeting its 
host for its iron. One of the methods by which M. tuberculosis can obtain iron from its host is 
through the development of siderophores, which are iron-binding molecules (Schaible & 
Kaufmann, 2004). M. tuberculosis produces two types of siderophores, namely 
carboxymycobactins and exochelins. The highest concentrations of siderophores are 
produced when the bacterium is grown in iron-limited conditions, as in the case of TB 
infection when the host limits the bacterium‟s interaction with its iron stores (Ratledge, 
2004). 
Mycobactins, of which carboxymycobactins are a variant containing a carboxylic acid group, 
have a high affinity for iron, as do exochelins. The term exochelin is a dated term still used in 
some studies as a collective term for all extracellular siderophores which are found in 
mycobacteria (Ratledge, 2004). With the development of these siderophores, M. tuberculosis 
is able to sequester iron from host cells despite having to compete with host iron-binding 
proteins such as transferrin (TF) and lactotransferrin (LTF) (Olakanmi et al., 2007). Apart 
from the development of siderophores, mycobacteria have the ability to block the maturation 
of the phagosome and its subsequent phago-lysosomal fusion within host macrophages 
(Schaible & Kaufmann, 2004; Saunders & Britton, 2007). The exact mechanism by which the 
Stellenbosch University http://scholar.sun.ac.za
  Chapter 1: Literature Review 
 
9 
 
bacterium does this is unclear but can at least partly be attributed to the ability of M. 
tuberculosis to hydrolyze phosphatidylinositol 3-phosphate, which is a lipid required for 
phago-lysosomal fusion (Vergne et al., 2005). Since the phagosome does not fuse with a 
lysosome and the pH environment of the phagosome does not become acidic, the bacteria can 
proliferate freely without being destroyed. 
The relationship between iron and pathogenic infection is being widely explored. Schaible 
and Kaufmann (2004) previously observed that individuals with higher iron levels in their 
system are more susceptible to pathogenic infection, not only from M. tuberculosis but from a 
number of other bacteria. Furthermore, Gordeuk et al. (1996), Schaible et al. (2002), and 
Cronjé et al. (2005) have suggested that there is an association between the metabolism of 
iron – and more specifically iron overload – and M. tuberculosis susceptibility. Lounis et al. 
(2001) provided unequivocal evidence that M. tuberculosis infections are enhanced by 
increased iron levels in mice. These researchers go on to suggest that further study on the 
relationship between iron and M. tuberculosis is merited. 
 
1.3 IRON IN THE HUMAN BODY 
1.3.1 Overview 
Iron is not only important for bacterial proliferation but is an essential element required by 
almost all forms of life, except perhaps lactic acid bacteria, where it acts as both an electron 
acceptor and donor in many crucial reduction-oxidation (redox) reactions (Ong et al., 2006). 
Since iron has this property, it plays a critical role in many physiological processes such as 
DNA biosynthesis, gene regulation, oxygen transport, respiration, and the citric acid cycle 
(for energy production), and for the incorporation into proteins as a co-factor; all of which are 
necessary for the existence of many organisms.  
The human body contains approximately 3 to 5 g of iron at any one time, depending on the 
weight and gender of an individual (Papanikolaou & Pantopoulos, 2005). An example of the 
difference that gender makes is that women tend to have slightly less iron in their bodies 
compared to men, which is explained by iron lost through blood loss during menstruation.  
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Figure 1.3 Distribution of iron in the human body. Iron is absorbed in the duodenum by the brush border epithelial cells. 
Iron contained within the muscles is primarily found within myoglobin while the iron within red blood cells and bone 
marrow is primarily found in haemoglobin. Liver iron is mostly stored within ferritin where it serves as the body‟s main 
storage site for iron. Redrawn from Papanikolaou & Pantopoulos (2005). 
 
The daily diet of an average individual contains roughly 15 mg of iron of which only 1 to 
2 mg is absorbed (Ganz, 2007). Iron is mainly stored in haem and forms part of haemoglobin, 
which is used to transport oxygen in red blood cells via the bloodstream, and myoglobin, 
which is stored in muscle tissue. The other primary repository for iron is within the ferritin 
protein found in the liver (the major iron storage organ). Ferritin is a protein with the unique 
ability to form a hollow core that allows for the storage of up to 4 500 iron ions at a time 
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(Ong et al., 2006). The remaining distribution of iron in the body can be seen in Figure 1.2. 
The largest portion of iron within the body originates from erythrocytes (Papanikolaou & 
Pantopoulos, 2005). Large amounts of iron are required for erythropoiesis and is supplied 
through the recycling of senescent erythrocytes by the reticuloendothelial macrophages. The 
recycled iron is then returned to the plasma to be bound to TF. 
Too much iron can be detrimental for the body and can lead to disorders such as hereditary 
haemochromatosis (iron overload), while too little iron is also harmful and can lead to 
anaemia (Schaible & Kaufmann, 2004). Since there is no physiological excretion mechanism 
for iron other than being lost through sloughing of mucosal cells, menstruation, and other 
blood loss, and since so little is absorbed daily from food intake, it is imperative to tightly 
regulate absorption, storage and transport of iron throughout the body in order to maintain 
iron homeostasis (Papanikolaou & Pantopoulos, 2005). These processes are briefly discussed 
in the sections to follow and Figure 1.4 illustrates these processes. 
 
1.3.2 Iron Absorption and Storage 
Once food in the form of the bolus enters the duodenum, the brush border epithelial cells 
absorb iron and other nutrients required by the body (McKie et al., 2001). The iron that is 
absorbed is either non-haem bound or haem bound in nature. In the alkaline pH environment 
of the duodenum (pH 7.0-8.5), non-haem bound iron is predominantly found in the ferric 
(Fe
3+
) form, which is highly insoluble (Miret et al., 2003). In order to be absorbed, it is 
necessary for the iron to be reduced from ferric to ferrous (Fe
2+
) iron, which is the soluble 
form. This reduction is facilitated by the duodenal cytochrome B (DCYTB) protein, as 
illustrated in Figure 1.4. 
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Figure 1.4 The absorption, storage and transport of iron. Iron is absorbed from the gut lumen in either its haem bound or non-haem bound state. Non-haem bound iron is absorbed by divalent 
metal transporter 1 (DMT1) in conjunction with duodenal cytochrome b (DCYTB) which reduces the iron to its Fe2+ form. Haem-bound iron is absorbed by haem carrier protein 1 (HCP1). Iron 
is then either stored in ferritin or transported out of the cell to an alternative tissue. Iron is exported from the cell by the interaction of ferroportin (FPN), an iron transporter, and hephaestin 
(HEPH), a ferroxidase, so that it is present in the bloodstream in its Fe3+ form. The proteins transferrin (TF) and lactotransferrin (LTF) bind iron in the bloodstream in order to facilitate its 
transport to cells that require it. TF binds to transferrin receptor (TFR) and the entire complex is internalized in order to transport iron into a cell. There are protein regulators in the bloodstream 
in the form of hepcidin (HEP), which regulates FPN, and haemochromatosis (HFE), which regulates TF. 
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The reduction of the iron allows for it to be transported into the cell by the divalent metal 
transporter 1 (DMT1) protein (Papanikolaou & Pantopoulos, 2005). Haem bound iron is 
absorbed into the cell by a protein known as haem carrier protein 1 (HCP1) and upon entry to 
the cell the iron is dissociated from the haem by a haem oxygenase (Raffin et al., 1974). Once 
Fe
2+
 enters the cell it is either exported into the bloodstream for use by the body or stored by 
ferritin binding. This is because this form of iron is highly unstable when unbound and may 
cause the formation of reactive oxygen or nitrogen intermediates (ROIs and RNIs 
respectively). These reactive intermediates can damage the cell during oxidative bursts and 
can lead to the formation of free radicals, which have been shown under some conditions to 
cause the development of cancer (Dreher & Junod, 1996). The storage site for iron within the 
cell is within the protein ferritin, which is primarily found in the liver (Papanikolaou & 
Pantopoulos, 2005). When iron is required elsewhere in the body it is exported into the 
bloodstream where it can be transported to the tissue where it is required. 
1.3.3 Iron Transport 
Iron is exported from the cell by the only known iron transport protein known as ferroportin 
(FPN). In favourable conditions, the pH of blood is neutral (pH 7.0-7.4), which favours the 
formation of Fe
3+
 (Vaupel et al., 1989). However, for iron to be bound in the bloodstream it 
needs to be oxidised into its more stable and insoluble Fe
3+
 form. A ferroxidase, such as 
hephaestin (membrane-bound) or ceruloplasmin (unbound in the bloodstream), facilitates the 
oxidation of Fe
2+
 into Fe3
+
 and is then exported from the cell into the bloodstream (Ganz, 
2007; Geissler & Singh, 2011). Once in the bloodstream, Fe
3+
 binds to either TF or its 
homolog LTF. The transferrin family (including TF and LTF) can bind two Fe
3+
 ions at a 
time and these globular proteins allow for the movement of iron throughout the body 
(Papanikolaou & Pantopoulos, 2005). 
When iron bound to TF (TF-Fe
3+
) needs to be imported into an awaiting cell, this complex 
must first bind to a cell surface receptor known as the transferrin receptor (TFR) (Levy et al., 
1999; Ponka et al., 1998). Once the TF-Fe
3+
 molecule is bound to TFR, the complex is 
internalised via endocytosis and subsequently iron is imported into the cell. Unlike TF, LTF 
is not required to bind to TFR in order to import iron into the cell, but the exact mechanism 
by which it does this is poorly understood, and it is thought LTF receptors may be involved 
(Papanikolaou & Pantopoulos, 2005). 
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1.4 GENES UNDER INVESTIGATION 
The scope of this thesis is to investigate the promoter region of genes involved in the iron 
metabolism pathway and whether there is a correlation with M. tuberculosis susceptibility. 
Five genes were chosen to be investigated in this study based on their importance in iron 
metabolism, namely in absorption (CYBRD1), regulation (HAMP and HFE), transport (LTF), 
and export (SLC40A1). Information on these genes regarding their structure, length, protein 
product, orientation, and general function are given in Table 1.1. 
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Table 1.1 General information for genes under investigation 
GENE INFORMATION PROTEIN INFORMATION 
Name (symbol) 
Encode accession 
number 
Length (bp) 
Genome position 
(orientation) 
Chromosome 
position 
Number of 
exons 
Product 
Length (amino 
acid residues) 
Weight (kilo 
Daltons) 
General 
function 
Cytochrome B 
Reductase 1 
(CYBRD1) 
ENSG00000071967 35 887 
172 378 757 – 
172 414 643 
(plus strand) 
2q31.1 4 
Duodenal 
cytochrome B 
(DCYTB) 
286 32 
Reduces Fe3+ to 
Fe2+ 
Hepcidin Anti-
Microbial Peptide 
(HAMP) 
ENSG00000105697 2 637 
35 773 410 – 
35 776 046 (plus 
strand) 
19q13.1 3 Hepcidin 84 (25*) 9 
Binds to FPN 
which results in 
FPN 
degradation 
Haemochromatosis 
(HFE) 
ENSG00000010704 11 124 
26 087 448 – 
26 098 571 (plus 
strand) 
6p21.3 7 
Haemochromatosis 
(HFE) 
348 40 
Binds to TFR; 
inhibits TF 
binding 
Lactotransferrin 
(LTF) 
ENSG00000012223 49 589 
46 477 136 – 
46 526 724 
(minus strand) 
3p21.31 17 
Lactotransferrin 
(LTF) 
710 78 
Iron transport 
in macrophages 
Solute Carrier 
Family 40 Member 
A1 (SLC40A1) 
ENSG00000138449 23 180 
190 425 305 – 
190 448 484 
(minus strand) 
2q32.2 8 Ferroportin (FPN) 571 63 
Iron export 
from cell 
*The peptide length given is for that of the prepropeptide whereas the most common form of the mature peptide is indicated in brackets. Abbreviations: bp = base pairs; CYBRD1 = cytochrome 
B reductase 1 gene; DCYTB = duodenal cytochrome B protein; FPN = ferroportin protein; HAMP = hepcidin antimicrobial peptide gene; HFE = Haemochromatosis gene; HFE = 
Haemochromatosis protein; LTF = lactotransferrin gene; LTF = lactotransferrin protein; SLC40A1 = solute carrier family 40 member A1 gene 
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1.4.1 Cytochrome b reductase 1 (CYBRD1) 
At physiological pH (ideally pH 7.4), iron is predominantly found in the Fe
3+
 insoluble form 
(Miret et al., 2003). In order for a cell to take up iron, the iron needs to be in the Fe
2+
 form, 
which is soluble. However, the Fe
2+
 form is highly unstable and can facilitate the formation 
of ROIs and so will quickly be oxidised into the Fe
3+
 form. Although these reactive oxygen 
species (ROS) have a potentially anti-microbial function, the presence of too many may lead 
to the formation of free radicals and have a cytotoxic effect on the cell (Bjorstad, 2009; 
Martin et al., 2004). In order for the iron to be reduced to its ferrous form the body has to 
produce iron reductases to facilitate the reaction (McKie et al., 2001). One such iron 
reductase is DCYTB, which is produced by the gene CYBRD1. This membrane protein is 
highly expressed in the duodenal brush border membrane, i.e., the enterocytes, and also 
operates in the airway epithelial cells (Oakhill et al., 2008; Collins, 2008). Since it is only 
possible to take up iron in its soluble form, ferric reductases are crucial proteins involved in 
the absorption of iron by cells in the body. DCYTB is not the only ferric reductase present in 
the body but it is one of the most important because it aids in the regulation of iron absorption 
from the diet. DCYTB reduces iron so that the DMT1 protein (also known as NRAMP2) can 
import the iron into the cell (Papanikolaou & Pantopoulos, 2005). 
Mutations in this gene have been associated with primary iron overload and anaemia, 
although the mechanism by which this occurs requires further elucidation (Zaahl et al., 2004). 
The sequence of this gene is classified as belonging to the cytochrome b561 family (Oakhill et 
al., 2008). The cytochromes b561 are a class of intrinsic membrane proteins that play a role in 
ascorbate (vitamin C) regeneration (Verelst & Asard, 2003). These are multi-pass membrane 
proteins that non-covalently bind 2 haem molecules. It is likely that the structural features of 
the cytochrome b561 family members, for example that they are highly hydrophobic and 
contain 6 transmembrane helices, play an important role in their functioning. It is thought that 
prokaryotes do not have cytochromes b561 and that their function in eukaryotes must be 
essential as they are relatively conserved between species in terms of the inner 4 helices 
found in the protein. 
It has been postulated that DCYTB plays a role as a co-factor in the NADPH oxidase 
dependent respiratory burst (Collins, 2008). One hypothesis, put forward by Collins (2008), is 
that DCYTB levels are elevated in individuals experiencing microbial infection because the 
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protein allows for an ample supply of ferrous iron to be available to act as a co-factor for 
NADPH oxidase-mediated anti-microbial functions; this is supported by unpublished 
observations in which Dcytb-deficient mice showed reduced production of ROS. 
 
1.4.2 Hepcidin Antimicrobial Peptide (HAMP) 
Hepcidin is considered a major regulator of iron levels in the bloodstream since it inhibits the 
export of iron from the cell. It does this by causing the internalisation and eventual 
degradation of the FPN protein responsible for exporting iron out of the cell (Collins, 2008). 
In order to perform this function, hepcidin has specific domains that recognise FPN and allow 
the two proteins to interact. The hepcidin protein is encoded for by the HAMP gene.  
Mutations in this gene have been associated with Haemochromatosis type 2B, also known as 
Juvenile Haemochromatosis (Papanikolaou et al., 2005). This disorder affects iron 
metabolism by causing excess iron to be deposited in tissue, which results in typical 
Haemochromatosis symptoms, including bronzing of the skin, cirrhosis, diabetes mellitus and 
cardiomyopathy (Nandar & Connor, 2011). It is called Juvenile Haemochromatosis because it 
presents at an early age unlike type 1 Haemochromatosis, which only presents later in life. 
This prepropeptide is secreted by the liver to aid in the regulation of iron metabolism and is 
cleaved into different forms, ranging from 20 to 25 amino acids in length; the predominant 
form found in humans is that of hepcidin-25 (25 amino acids long) as indicated in Table 1.1 
(Ganz, 2003). 
Hepcidin is produced in response to high iron levels and inflammation and has also been 
shown to be produced in response to bacterial infection since it has antimicrobial activity and 
inhibits pathogen proliferation (Collins, 2008; De Domenico et al., 2007; Ganz, 2003). The 
interaction between FPN and hepcidin inhibits iron from leaving the cell and in this way it 
prohibits bacterial growth by reducing iron availability to pathogens that sequester iron from 
the bloodstream (Ward et al., 2011). Such pathogens include those that infect the gut, e.g., E. 
coli (Park et al., 2001). Although the activity of hepcidin does not allow for the proliferation 
of pathogens that reproduce in the bloodstream, it creates the ideal environment for pathogens 
that infect from within cells, such as the infection of macrophages by M. tuberculosis, since it 
causes large amounts of iron to collect within the cell (Collins, 2008).  
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1.4.3 HFE (Haemochromatosis gene) 
The other protein considered to be a major regulator of iron homeostasis is HFE. The HFE 
protein is encoded for by the gene HFE. This protein controls iron absorption by regulating 
the interaction between the TFR and TF. In order for iron to move into a cell it must be bound 
to TF in the blood. The TF-iron complex then binds to the surface protein TFR and this whole 
complex is then internalised, thereby moving iron into the cell (Nandar & Connor, 2011). The 
HFE protein binds to TFR and reduces TFR‟s affinity for TF. Since less TF-iron complexes 
are able to bind to TFR, the amount of iron that can be given by TF to a cell that requires it is 
reduced. This theory is under debate as some research has shown that the HFE protein can 
inhibit iron from entering the cell even when it cannot bind to TFR (Zhang et al., 2003). 
Zhang and his colleagues (2003) used a mutated form of HFE that has a 5 000-fold decrease 
in affinity for TFR but could still bind beta-2-microglobulin and was not misfolded. They 
showed that cells with the mutated as well as the wild type HFE accumulated 30% less iron 
than cells with a non-functional form of HFE. This suggests that HFE might interact with a 
number of proteins which could affect the binding of the TF-iron complex to TFR in a 
cascade type manner. Mutations in this gene have most commonly been linked to the genetic 
iron overload disorder Hereditary Haemochromatosis. This disease is characterised by the 
accumulation of iron in tissues such as the liver, heart, and brain, and can result in symptoms 
such as cirrhosis, cardiomyopathy, diabetes mellitus, arthritis and, more speculatively, 
neurodegenerative disorders such as Alzheimer‟s disease (Allen et al., 2008; Nandar & 
Connor, 2011) 
The protein product is a membrane protein similar to major histocompatibility complex 
(MHC) class-I type proteins (Feder et al., 1996). This protein consists of two alpha 
extracellular domains and a third alpha domain which spans the cell membrane. This third 
alpha region binds to beta-2-microglobulin which is involved in the innate immune system 
(Lebron et al., 1998). Notably, this protein contains a histidine cluster, which is thought to be 
a binding site for iron as it is similar to some iron-binding sites seen in other proteins. 
Although a direct link has yet to be shown between the HFE protein and the host immune 
system, MHC class-I type proteins have previously been shown to play a role in the immune 
system and specifically in the cytoplasm during M. tuberculosis infection (Fairbairn, 2004) 
and thus it could be proposed that the HFE protein also plays a role in immunity. The HFE 
protein also contains a C1-set domain, which is almost exclusively found in proteins involved 
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in the immune system (Pamer & Cresswell, 1998). This further strengthens the hypothesis 
that HFE plays a role in the immune system. 
 
1.4.4 Ferroportin (SLC40A1) 
Once iron is absorbed from the gut by the lining epithelial cells it has to be directed to the 
bloodstream to reach tissues in the body that require it. For this to occur the iron needs to be 
oxidised to its ferric form so that it can be bound to TF once in the bloodstream. SLC40A1 is 
the iron gene which encodes for the only known FPN responsible for the regulation of iron 
efflux from duodenal epithelial cells (Collins, 2008). The FPN protein mediates the efflux of 
iron in the presence of a ferroxidase, such as hephaestin (membrane-bound) or ceruloplasmin 
(free in the plasma), which is required to oxidise the iron to Fe
3+ 
in order for its movement 
out of the cell to occur (Geissler & Singh, 2011). Mutations in this gene have most commonly 
been linked to Hereditary Haemochromatosis type 4, or FPN disease, which is inherited in a 
dominant negative fashion (Pietrangelo, 2004). This disease can present in two manners. The 
mutated protein is changed so that hepcidin can no longer bind and regulate the protein thus 
resulting in increased transferrin saturation as more iron is present in the bloodstream. 
Alternatively, the mutated protein loses its function and iron accumulates in the cell because 
it cannot be exported to the bloodstream resulting in decreased transferrin saturation. 
FPN is a multi-pass transmembrane protein which contains anywhere from 9 to 12 
transmembrane domains depending on the researchers (Wallace et al., 2010). Most 
researchers agree, however, that it is more likely that there are 12 transmembrane domains in 
the FPN protein (Liu et al., 2005). This protein also carries a domain for the specific 
recognition of the hepcidin protein (Wallace et al., 2010). 
FPN is regulated by the protein hepcidin in order to control the efflux of iron from the cell 
(Collins, 2008). During bacterial infection, the body produces more hepcidin in order to 
degrade FPN and thus inhibits iron export out of the cell. In this way bacterial infection is 
supposed to inhibit bacteria that sequester their iron from the bloodstream. In the case of 
bacteria such as M. tuberculosis, the iron is sequestered from within the cell – in this instance 
the macrophage – and so the degradation of FPN actually allows for the proliferation of these 
pathogens. Recently researchers have shown that 4 single nucleotide polymorphisms (SNPs) 
in the SLC40A1 gene have been associated with an increased risk of development of 
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tuberculosis and 1 SNP in this gene has been associated with a decreased risk for the 
development of the disease (Baker et al., 2012). 
 
1.4.5 Lactotransferrin (LTF) 
Since iron is required by many tissues in the body, a transport mechanism is required to 
deliver it to its destination. This transport is facilitated by either the TF protein or its closely 
homologous relative, LTF. The main difference between TF and LTF is that TF must bind to 
TFR in order for iron to move into the cell whereas LTF does not require this interaction. 
Another difference is that TF is the main iron binding transport protein in the serum and is 
found in all regions where iron transport is required, whereas LTF is mainly found at mucosal 
membranes (Olakanmi et al., 2007). Mutations in this gene have been associated with a 
number of diseases, such as cystic fibrosis, Sjogren‟s syndrome and Alzheimer‟s disease 
(Moskwa et al., 2007; Ohashi et al., 2003; Kawamata et al., 1993). 
LTF is part of the transferrin family (a major iron-binding protein) and is predominantly 
found in secondary granules of neutrophils within milk and bodily secretions, and it functions 
in close association with the body‟s immune system as it has antimicrobial activity (Singh et 
al., 2002; Orsi, 2004). This globular glycoprotein has been implicated in the transferred 
immunity from mother to infant via breast milk, which contains a high concentration of LTF. 
It is thought to aid in strengthening the infant‟s immune system against pathogenic infection 
(Wheeler et al., 2007). The LTF protein is folded into two lobes, viz. the carboxyl (C-) and 
the amino (N-) terminal halves, which are joined by an α-helix (Baker & Baker, 2005; Ward 
et al., 1996). The lobes are further sub-divided into two α/β domains designated N1 and N2, 
or C1 and C2, depending on the lobe in question, in which a deep cleft can be found, which is 
the binding site for iron (Baker & Baker, 2005). These lobes have a high affinity for iron and 
reversibly bind this molecule when required. 
LTF is produced by the macrophages in response to high serum iron concentrations and 
pathogen infection (Ward et al., 2011). LTF‟s main function is to bind iron and transport it to 
the small intestine and other parts of the body. LTF also regulates iron homeostasis as part of 
the non-specific immune system, and by doing so regulates cell growth and differentiation 
(Horiuchi et al., 2009). TFs can bind two Fe
3+
 ions in association with an anion, such as 
bicarbonate, and by doing so facilitate the transport of iron throughout the body. Unlike TF, 
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LTF has antimicrobial activity that acts in two ways: first, a bacteriostatic activity that 
inhibits bacteria from sequestering iron by competing with them; and second, a bacteriocidal 
activity by which LTF binds to the outer membrane of bacteria with high lipopolysaccharide 
contents, thereby increasing bacterial membrane permeability by causing the release of 
polysaccharides (Orsi, 2004). By increasing the bacterial membrane‟s permeability, the 
pathogen becomes more vulnerable to breakdown by phagosomes within the macrophage 
(Ellison et al., 1988). LTF can also stimulate the production of apoptotic signals within an 
infected cell so that it is destroyed before bacterial infection can spread (Orsi, 2004). M. 
tuberculosis has been shown to have the ability to acquire iron from both the cytoplasm of the 
macrophage (endogenous), as well as from TF and LTF found extracellularly (exogenous) 
(Olakanmi et al., 2007). However, it has also been shown that M. tuberculosis acquires two- 
to three-fold more iron from LTF than from TF. This phenomenon most likely occurs 
because iron acquisition from TF involves TFR-mediated endocytosis whereas LTF does not 
and thus the pathogen has less competition for binding of the iron; and because LTF is the 
major iron-binding protein in the airway of humans and so would be more prevalent in this 
region than TF (Olakanmi et al., 2007; Finkelstein et al., 1983; Quinlan et al., 2002; 
Richardson & Ponka, 1997).  
 
1.5 TRANSCRIPTIONAL REGULATION OF GENES INVOLVED IN IRON 
METABOLISM 
1.5.1 Overview 
Iron homeostasis is necessary for the normal functioning of the body and thus the tight 
regulation of the genes that maintain iron is very important. One of the mechanisms for 
controlling these genes is through transcriptional regulation, which, as the name suggests, 
occurs during transcription. Another mechanism is through post-transcriptional regulation. In 
this way the mRNA produced through transcription is either stabilised or degraded as 
required (Papanikolaou & Pantopoulos, 2005). 
Promoters are regions of DNA comprising cis-regulatory elements because they regulate the 
expression of DNA adjacent to them and are generally found upstream of a gene (Sandelin et 
al., 2007). Promoters may be composed of varying combinations of recognition sequences 
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necessary for the binding of RNA polymerase II, the various transcription factors required for 
transcription and enhancers, but the exact composition of these promoters differs between 
genes. 
Two forms of transcription initiation exist, namely focused and dispersed transcription 
initiation (Juven-Gershon & Kadonaga, 2010). During focused initiation, a single nucleotide, 
or small areas of several nucleotides, is responsible for the start of transcription. In contrast, 
during dispersed initiation, many weak start sites over a broad region are responsible for 
transcription to initiate. This type of promoter has also been referred to as a broad distribution 
(BR) promoter (Carninci et al., 2006). BR promoters have been found to be more abundant 
than single start site promoters and typically occur in CpG islands (Juven-Gershon & 
Kadonaga, 2010). BR promoters tend to lack the BRE, TATA and DPE motifs commonly 
found in focussed initiation promoters (Sandelin et al., 2007; Carninci et al., 2006). 
The promoter motifs discussed previously represent the most studied and simplest forms and 
do not encompass all known promoters. Furthermore, promoters are not the only motifs or 
regions of DNA that control gene expression (Juven-Gershon & Kadonaga, 2010). The subtle 
control of the interactions between both cis- and trans-regulatory elements is crucial to the 
precise expression of genes in terms of both spatial and temporal requirements in the body, 
and this is especially true for genes involved in the metabolism of a nutrient as important as 
iron. The regulatory elements involved in the expression of genes involved in iron 
metabolism are currently poorly understood; some of the known elements are described in the 
following sections. 
 
1.5.2 Iron Response Elements (IREs) 
Iron response elements (IREs) are hairpin structures that serve as transcription factor binding 
sites located in either the five prime (5‟) or three prime (3‟) untranslated regions (UTRs) of 
genes known to be involved in iron metabolism (Hentze & Kuhnt, 1996). The IREs are 
recognised by a specific protein named the iron-regulatory protein (IRP) of which two 
homologs exist, IRP1 and IRP2 (Hentze & Kuhnt, 1996; Papanikolaou & Pantopoulos, 
2005). This interaction is illustrated in Figure 1.3.  
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Figure 1.5 The interaction of IRE and IRP in mRNA regulation. In conditions of low iron availability the IRP/IRE interaction allows for the increased expression of the transferrin receptor 
(TFR1) and decreased expression of ferritin, ALAS2 and m-aconitase. In this manner more iron will be able to enter the cell and less will be stored increasing the overall iron pool within the 
cell. Conversely, in high iron conditions the IRP protein is either degraded or inactive and cannot bind to IREs. This results in the destabilization of TFR mRNA and the simultaneous initiation 
of the binding of the small ribosomal subunit to the mRNA of ferritin, ALAS2 and m-aconitase which allows for translation to take place. In this way TFR expression is reduced and less iron 
can enter the cell. More iron is now stored in ferritin as more ferritin is being produced and this decreases the overall iron pool within the cell. Redrawn from Papanikolaou & Pantopoulos, 2005. 
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A common example of an IRE occurring in the 3‟UTR of mRNA is that of the mRNA of 
TFR. During times of low iron levels, the IRP protein is active and binds to the IRE of the 
mRNA of TFR in its 3‟UTR. The binding of IRP to the IRE in this region stabilises the 
normally unstable TFR mRNA and less degradation occurs by RNase. This results in 
increased expression of TFR and thus more iron is taken up into the cell (Papanikolaou & 
Pantopoulos, 2005). Conversely, when the cell is experiencing high iron levels, the IRP 
proteins are either inactivated (IRP1) or degraded (IRP2) and thus do not bind to TFR‟s 
mRNA. This causes the destabilization of the mRNA, which results in the decreased 
expression of TFR and less iron taken into the cell (Hentze & Kuhnt, 1996).  
An example of an IRE occurring in the 5‟UTR is that of ferritin (but it is also known to occur 
in the ALAS2 and m-aconitase genes) (Papanikolaou & Pantopoulos, 2005). In circumstances 
when the internal levels of iron are high within the cell more ferritin needs to be produced in 
order to store the iron and negate any negative effect it might have while unbound in the cell. 
During this time, the IRP protein is inactive or degraded and thus cannot bind to the IRE in 
the 5‟UTR of the ferritin mRNA. This results in the normal translation of the mRNA and thus 
the increased expression of ferritin, which eventually leads to the decrease in intracellular 
iron. When the cell is depleted of iron the IRP proteins are active and can then bind to the 
IRE within ferritin‟s mRNA. This binding of IRP to the IRE prevents the 43S pre-initiation 
complex (the small ribosomal subunit) which facilitates the initiation of translation from 
binding and in this way inhibits the expression of ferritin (Hentze & Kuhnt, 1996). This will 
result in less ferritin being formed and less iron being stored and the eventual increase of free 
iron within the cell. 
 
1.5.3 Other Regulatory Elements 
The IRE transcription factor binding site is possibly the best characterised of all the binding 
sites involved in genes regulating iron homeostasis but is not the only binding site known. 
Other binding sites and their interacting proteins include: the GATA-box and its interaction 
with GATA- and its co-factor Friend of GATA (FOG), which have been shown to regulate 
the expression of the HFE gene; the CCAAT/enhancer-binding protein site, cyclic AMP 
response element-binding protein site, bone morphogenetic protein-response element site, 
and signal transducer and activator of transcription 3-response element site which are all 
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known to play a role in HAMP regulation; and the known interaction of binding factors such 
as SP1, SP3, IKLF with the promoter region of the LTF gene, which also contains response 
elements such as the TATA box and GATAAA (Bagu & Santos, 2011; Teng, 2002). 
Although there are many known interactions that regulate the expression of genes involved in 
iron homeostasis, the exact mechanism by which this regulation occurs and why there are 
differences in expression during developmental stages of these genes is still poorly 
understood, emphasizing the importance of research into these fields (Hentze & Kuhnt, 
1996). 
 
1.6 AIM AND OBJECTIVES 
The aim of this study is to elucidate the role of five genes involved in iron metabolism – 
CYBRD1, HAMP, HFE, LTF and SLC40A1 – in relation to M. tuberculosis susceptibility.  
 
The key objectives identified in order to achieve this aim are:  
1) to identify a cohort suitable for this study consisting of TB patients and healthy 
population-matched controls; 
2) to determine the iron parameters (including serum-iron, serum-ferritin, serum-transferrin 
and transferrin saturation percentage) for the entire cohort; 
3) to genotype the cohort for the promoter region of the five genes for novel and/or known 
variants; 
4) to determine allele and genotype frequencies for the data; 
5) to determine the effect of each identified variant through in silico analyses; and 
6) to perform statistical analyses to determine whether there are any correlations between 
the identified variants, iron parameters measured and the susceptibility to M. 
tuberculosis. 
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2. DETAILED EXPERIMENTAL PROCEDURES 
2.1 COHORT SAMPLING 
2.1.1 Patient and Control Groups 
This project has been granted ethical approval from the Research and Ethics/Biosafety 
Committee, Faculty of Health Sciences, University of Stellenbosch (N10/06/194). The cohort 
consisted of Black, Xhosa-speaking individuals. The patient group consisted of 49 TB 
patients (29 males; 20 females). Whole blood samples from the patients were obtained from 
the Ikhwezi Clinic in Somerset West. The controls group consisted of 51 individuals in total. 
This group was further split for genotyping purposes depending on their ability to amplify 
and quality of genotyping. The first control group consisted of 29 healthy individuals (11 
males; 18 females). For the patient group the mean age is 31.6 (standard deviation [S.D.] 
±7.21) with an age range of 21-48. For the control group the mean age is 46.5 (S.D. ±12.17) 
with an age range of 25-66. This group was used to genotype the promoter region of all five 
genes under investigation. 
For the CYBRD1 genotyping comparisons the above-mentioned controls could not all be 
amplified and so a second control group was added for comparison. The samples from this 
control group originated from a previous study and as such do not have iron parameter data 
available. This group consisted of 22 healthy individuals (11 males; 11 females). The mean 
age for this group is 58.8 (S.D. ±14.2) with an age range of 40-89. 
 
2.1.2 Iron Parameter Data 
BD Vacutainer® SST™ Serum Separation Tubes were used for blood collection from patient 
and control groups to determine iron parameters. The following parameters, with reference 
ranges shown in brackets, were measured: serum ferritin (reference range: 15-322 µg/l), 
serum iron (reference range: 9-30 µmol/l), serum transferrin (reference range: 1.74-3.60 g/l) 
and transferrin saturation percentage (%) (reference range: 20-55%). The data for C-Reactive 
Protein levels wer also included (reference range: 0-10 mg/l). The WHO (2004) has stressed 
Stellenbosch University http://scholar.sun.ac.za
  Chapter 2: Detailed Experimental Procedures 
 
  
28 
 
the importance of the establishment of standard reference ranges for iron parameters and so, 
at their suggestion, reference ranges for these parameters were obtained from these 
laboratories where the assays were performed (Davies Pathology and the NHLS). 
2.1.3 DNA Extraction 
Ethylenediaminetetraacetic acid (EDTA) tubes were used for the collection of blood for DNA 
extraction. DNA was extracted from whole blood samples using an adaptation of the Miller 
method (Miller et al., 1988). Whole blood (10 ml) was transferred to a 50 ml polypropylene 
tube. Cold Cell Lysis Buffer (CLB) (final concentration : 116.25 mM NH4Cl; 0.75 mM 
KHCO3; 0.075 mM EDTA) was added and this was mixed by inversion. This solution was 
then placed on ice for 15-30 minutes (mixing by inversion being performed every 5 minutes). 
The tubes were centrifuged for 15 minutes at 1 500 rpm on a Hermle Z200A centrifuge 
(Labnet) and the supernatant discarded thereafter.  
Subsequently, 10 ml of cold Phosphate Buffer Saline (PBS) (final concentration: 0.027 M 
KCl; 137 mM NaCl; 8 mM Na2HPO4; 1.5 mM KH2PO4) was added to the pellet which was 
then mixed and centrifuged for 10 minutes at 1 500 rpm (Hermle Z200A centrifuge) 
(Labnet). The supernatant was, once again, discarded and the pellet dissolved in Nuclear 
Lysis Buffer (NLB) (final concentration: 9 mM Tris-Cl; 0.3604 M NaCl; 1.8 mM EDTA; 
solution set to pH 8.2 using concentrated HCl), Proteinase K (final concentration: 0.09 
mg/ml) (Sigma) and 0.909% (w/v) Sodium Dodecyl Sulphate (SDS). This solution was 
mixed and incubated overnight at 56ºC in a water bath. The following day NaCl (final 
concentration: 1.3857 M) was added to the solution and shaken vigorously for 1 minute. This 
solution was centrifuged for 20 minutes at 2 500 rpm on a Hermle Z200A centrifuge (Labnet) 
at room temperature. Thereafter the supernatant was transferred to a clean 50 ml 
polypropylene tube. 
 Three volumes of ice cold ±99.9% (v/v) ethanol (EtOH) were added to one volume of the 
supernatant. The resulting contracted DNA bundle formed was removed with a needle and 
carefully placed into a microcentrifuge tube containing 70% (v/v) EtOH. This mixture was 
centrifuged at 4ºC for 5 minutes at 14 000 rpm on a Spectrafuge 16M centrifuge (Labnet). 
The ethanol was subsequently discarded and the pellet allowed to air dry. The pellet was 
resuspended in 100-500 µl of dH2O depending on the size of the pellet. Once the DNA was 
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resuspended the concentration and purity of each sample was determined through the use of a 
Nanodrop® ND-1000 Spectrophotometer v3.0.1 (NanoDrop Technologies Inc.). 
 
2.2 POLYMERASE CHAIN REACTION (PCR) AMPLIFICATION 
2.2.1 Oligonucleotide Primers 
Primers were designed to amplify the promoter region of each gene (up to 2 000 bp upstream 
of the first coding ATG). This region encompasses most of the transcription factor binding 
sites (TFBSs) necessary for gene expression as previously confirmed (Strickland, 2013). The 
reference sequences for CYBRD1, HAMP, HFE, LTF and SLC40A1 were obtained from 
Ensembl (www.ensembl.org). Two primer pairs were used to amplify two overlapping 
fragments for each gene promoter as indicated in Table 2.1. These fragments were subjected 
to semi-automated bi-directional sequencing analysis in order to identify novel/known 
variants. Tables 2.2 and 2.3 show the primer pairs used to amplify fragments used for 
genotyping the remaining samples either through Heteroduplex Single-Strand Conformation 
Polymorphism (HEX-SSCP) analysis (-1631 C/T, -323 C/T, -188 C/T [HAMP]; -1168 A/G, -
331 A/C [HFE]; -1377 T/G, -746 del AAA/ins AA, -457 T/C, -437 C/G [LTF]; -750 G/A, -
662 C/T, -501 T/C [SLC40A1]), Restriction Fragment Length Polymorphism (RFLP) analysis 
(-582 A/G [HAMP]; -561 A/G, -467 G/C [HFE]) or semi-automated bi-directional 
sequencing analysis (-1849 T/G, -1844 C/G, -1813 C/T, -1749 del (T)6G, -1540 G/A, -1477 
G/A, -1459 T/C, -1346 T/C, -1272 T/C, -1011 T/A, -849 C/G, -627 T/C, -624 G/A, -492 A/G, 
-454 C/T, -449 C/G, -399 T/G, -397 A/C, -238 A/G, -166 C/G [CYBRD1]; -1470 C/T, -1461 
T/C, -1399 G/A, -1355 G/C, -1098 G/A [SLC40A1]). 
Primers were designed using PrimerQuest (Integrated DNA Technologies Inc.). Primers 
indicated by an asterisk in the tables were previously designed also using PrimerQuest 
(Integrated DNA Technologies) and were made available for use in this study.
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Table 2.1 Oligonucleotide primers and PCR conditions for amplification of DNA for semi-automated bi-directional sequencing 
Gene 
Name 
Ensembl Accession 
Number 
Fragment Primer Name Primer Sequence (5‟- 3‟) 
Product 
Size (bp) 
TM 
(°C) 
TA (°C) 
Mg2+ 
(mM) 
Betaine 
(%) 
PCR amplification 
cycle 
Enzyme 
used 
CYBRD1 ENSG00000071967 
1 
BP1F Seq AGCTCAAGTGATTCTCTTGCCT 
972 
56.3 
75/68 1.5 0 A  
BP1R Seq TAGAGGCTAAACAAGCACTGGC 57.2 
2 
BP2F Seq GGGTTCAGCTGGTCAGCATC 
855 
58.5 
61 2 0 B  
BP2R Seq ACTTCTTGGGGCTGTCTCCG 56.2 
            
HAMP ENSG00000105697 
1 
PP1F Seq CTGGTGACTTGGCTGACACT 
980 
57.2 
63 1 12 B  *PP2R TCAAGACTAGCCTGGGCAAC 57.1 
2 
*PP3F CACGCCTGGCTAAATTTGTT 
768 
54.0 
53 1.5 0 C  
PP2R Seq CCGAGTGACAGTCGCTTT 55.0 
            
HFE ENSG00000010704 
1 
HP1F Seq CGCCCGGCTAATTTTTGTAT 
866 
53.6 
N/O N/O N/O N/O N/O *HP2R ATAGGTAAGACCATGCACAG 51.7 
2 
*HP3F TGAGGTTTGGGCTGTATCTG 
919 
54.5 
66 3 0 B  *HP7R CTCAGGAGATGCCCAGTAA 53.6 
   
 
        
LTF ENSG00000012223 1 
*LP (NheI) AATGCTAGCGCTGAGCCTCTTGGTAGTGG 
961 
64.9 
69 2 0 D  
LP1R Seq TGGGCAACATAGGGAAACCCC 59.8 
LP2F Seq CACCACCATGCTGGGCTAATT 
969 
58.0 
LP2R Seq TAGTCTGCAAGCCCCTAGGAG 58.1 
            
SLC40A1 ENSG00000138449 
1 
SP1F Seq GACCCTATTCTCCACGGTTAGC 
926 
57.0 
55 1.5 0 C  *SP3R ATGCCACAGAGGCCGCTTTC 60.8 
2 
*SP3F GGGAGAGGAATGATGGTGA 
963 
54.1 
62/56 1.5 12 A  *SP6R GCTAACACTGTAGCTGAAGTTGG 55.7 
          
*Primers previously designed. Abbreviations: 5‟ = 5-prime; 3‟ = 3-prime; % = percentage; °C = degrees Celsius; bp = base pairs; CYBRD1 = cytochrome B reductase 1 gene; F = forward 
primer; HAMP = hepcidin antimicrobial peptide gene; HFE = Haemochromatosis gene; LTF = lactotransferrin gene; N/O = not optimised; R = reverse primer; SLC40A1 = solute carrier family 
40 member A1 gene; TA = annealing temperature; TM = melting temperature 
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Table 2.2 Oligonucleotide primers and PCR conditions for amplification of genotyping fragments 
Gene 
Name 
Variant Primer Name Primer Sequence (5‟- 3‟) 
Product 
Size (bp) 
TM 
(°C) 
TA (°C) 
Mg2+ 
(mM) 
Betaine 
(%) 
PCR 
amplification 
cycle 
Enzyme 
used 
CYBRD1 
-1849 T/G, -1844 C/G, -1813 C/T, -1749 del 
(T)6G, -1540 G/A, -1477 G/A, -1459 T/C, -
1346 T/C, -1272 T/C, -1011 T/A 
BP1F Seq AGCTCAAGTGATTCTCTTGCCT 
972 
56.3 
75/68 1.5 0 A  
BP1R Seq TAGAGGCTAAACAAGCACTGGC 57.2 
-849 C/G, -627 T/C, -624 G/A, -492 A/G, -454 
C/T, -449 C/G, -399 T/G, -397 A/C, -238 A/G, 
-166 C/G 
BP2F Seq GGGTTCAGCTGGTCAGCATC 
855 
58.5 
61 2 0 B  
BP2R Seq ACTTCTTGGGGCTGTCTCCG 56.2 
           
HAMP 
-1631 C/T 
PP1F Seq CTGGTGACTTGGCTGACACT 
153 
57.2 
55 1.5 0 E  
PP R rs66868858 CTGCAGTGCCTTCATTCCTTTC 56.6 
-582 A/G 
*PP3F CACGCCTGGCTAAATTTGTT 
326 
54.0 
55 1.5 0 E  *PP3R CACCACACGTGCATAGGTTC 56.2 
-323 C/T 
*PP5F AAGTGAGTGGAGGAGAGCG 
106 
56.5 
48 1.5 12 F  *PP4R CCATCACGATGTCATTCTGC 53.8 
-188 C/T 
PP F rs116178041 CAGAATGACATCGTGATGGG 
198 
53.3 
48 1.5 0 F  *PP5R CTTTGCTCTGTCTCATTTCC 51.2 
    
           
*Primers previously designed. Abbreviations: 5‟ = 5-prime; 3‟ = 3-prime; °C = degrees Celsius; bp = base pairs; CYBRD1 = cytochrome B reductase 1 gene; F = forward primer; HAMP = 
Hepcidin antimicrobial peptide gene; HFE = Haemochromatosis gene; LTF = lactotransferrin gene; R = reverse primer; SLC40A1 = solute carrier family 40 member A1 gene; TA = annealing 
temperature; TM = melting temperature 
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Table 2.3 Oligonucleotide primers and PCR conditions for amplification of genotyping fragments 
Gene 
Name 
Variant Primer Name Primer Sequence (5‟- 3‟) 
Product 
Size (bp) 
TM 
(°C) 
TA (°C) 
Mg2+ 
(mM) 
Betaine 
(%) 
PCR 
amplification 
cycle 
Enzyme 
used 
HFE 
-1168 A/G 
HP1F GGTTTGGAGCAAATCAGGTG 
335 
54.3 
57 1.5 0 E  
HP1R GTGCTGAGTTCACTTCGCAG 56.4 
-561 A/G 
*HP5F TTAGTGACAGCCTTTCCGCT 
145 
56.5 
48 1.5 0 F  
HP R novel -561 AGTATTGGGATTATCTGGAGAATGA 53.3 
-467 G/C 
HP F rs2794720 GCCTCAATATGTTTAATCATTCTCC 
213 
52.1 
55 1.5 0 E  
HP R rs2794720 ATCTCAACCTTAGACCAACTTATG 52.3 
-331 A/C 
HP F novel -331 GACATAAGTTGGTCTAAGGTTGAG 
115 
53.1 
48 1.5 0 F  *HP6R GGGAAAGTAGCTTCGCAATG 54.1 
           
LTF 
-1377 T/G 
LP1F GCCAAGAAAGGTGTTCAGGT 
153 
55.5 
62 1.5 0 E  
LP1R GTGGCAGTGAGCCATGAT 55.3 
-746 del AAA/ ins AA 
LP2F ACCATTTCCTACTGAATACTATCAACAC 
150 
54.7 
60 1.5 0 E  
LP2R CCACCCAAGGCTGGTTC 56.3 
-457 T/C 
LP3F GGGCAGGGAGATACCCCAT 
163 
59.0 
55 1.5 0 E  
LP3R GCCAGTTAGGGCAGGTG 56.0 
-437 C/G 
LP4F CACCTGCCCTAACTGGC 
182 
56.0 
55 1.5 0 E  
LP2R Seq TAGTCTGCAAGCCCCTAGGAG 58.1 
           
SLC40A1 
-1470 C/T, -1461 T/C, -1399 G/A, -
1355 G/C, -1098 G/A 
SP1F GTAGACCTTTGGGGCTCCTG 
738 
57.5 
55 1.5 12 B  
SP3R ATGCCACAGAGGCCGCTTTC 60.8 
-750 G/A 
SP4F GAAGCCCTGCTATGCAGTCC 
255 
58.3 
57 1.5 0 E  
SP4R GTCAGGTGCTGGAAGAAAGC 56.3 
-662 C/T 
SP F rs12693542 CAGCACCTGACGCTTAGTTT 
130 
55.4 
N/O N/O N/O N/O N/O 
SP R rs12693542 TTTCCTGCTCTCCGGGAA 56.0 
-501 T/C 
SP6AF TCCCGGAGAGCAGGAAAAC 
135 
57.2 
N/O N/O N/O N/O N/O 
SP5R CCGTCCCCGCGCCCTTGC 68.0 
*Primers previously designed. Abbreviations: 5‟ = 5-prime; 3‟ = 3-prime; °C = degrees Celsius; bp = base pairs; CYBRD1 = cytochrome B reductase 1 gene; F = forward primer; HAMP = 
Hepcidin antimicrobial peptide gene; HFE = Haemochromatosis gene; LTF = lactotransferrin gene; N/O = not optimised; R = reverse primer; SLC40A1 = solute carrier family 40 member A1 
gene; TA = annealing temperature; TM = melting temperature 
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Key to Tables 2.1 to 2.3 
Yellow = Pfu enzyme reaction 
Green = Taq enzyme from Thermo Fisher Scientific reaction 
Red = Taq enzyme from KAPABiosystems reaction 
Orange = Primers used for semi-automated bi-directional sequencing but not in PCR 
amplification 
Purple = Fragments intended to be genotyped through semi-automated bi-directional 
sequencing analysis 
Blue = Fragments intended to be genotyped through RFLP analysis 
Grey = Fragments intended to be genotyped through HEX-SSCP analysis 
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2.2.2 Amplification of Fragments 
2.2.2.1 Amplification of PCR Fragments 
As already mentioned, fifteen randomly selected samples were subjected to semi-automated 
bi-directional sequencing analysis. Reaction conditions for each promoter region were 
optimised and the PCR conditions used are stipulated in Table 2.1. An Applied Biosystems 
PCR thermocycler (Applied Biosystems model 2720 Thermal Cycler) was used to perform all 
PCR reactions. To confirm the presence of the target DNA, all PCR products were 
electrophoresed on a 0.8% (w/v) to 3% (w/v) horizontal agarose gel at 120 volts (see section 
2.2.3). The first fragment of HFE could not be optimised and a second set of primers (HP1F 
and HP1R as seen in Table 2.3) was used to amplify a smaller region to determine whether 
any variants were present. This fragment was analysed using HEX-SSCP analysis resulting in 
the discovery of a variant (-1168 A/G). The remaining population was thus genotyped for this 
variant. 
Table 2.1 shows the conditions for the initial screening of the population for variants. Upon 
genotyping these 15 samples, 40 variants were identified. The fragments chosen to genotype 
these variants and their optimised PCR conditions are shown in Tables 2.2 and 2.3. The 
remaining patient and control samples for the CYBRD1 promoter were amplified in the same 
manner as the original subset of fifteen and subsequently subjected to semi-automated bi-
directional sequencing analysis. A region of the SLC40A1 promoter containing five variants 
was amplified and also subjected to semi-automated bi-directional sequencing analysis. 
Three fragments were amplified for subsequent RFLP analysis to genotype three separate 
variants (Tables 2.2 and 2.3). Twelve fragments were amplified in order to be genotyped by 
HEX-SSCP analysis so as to genotype 12 separate variants (Tables 2.2 and 2.3). Two variants 
in the SLC40A1 promoter could not be optimised and were excluded from further analyses. 
 
2.2.2.2 PCR Reaction Reagents and Amplification Cycles 
The PCR reagents consisted of either a Pfu enzyme reaction, a Taq enzyme reaction from 
Thermo Fisher Scientific or a high fidelity Taq enzyme reaction from KAPABiosystems 
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depending on the fragment amplified. Each 25 μl Pfu enzyme reaction contained 50 ng of 
DNA, 1 X Pfu-buffer [20 mM Tris-HCL, 10 mM ammonium sulphate ((NH4)2SO4), 10 mM 
KCl, 0.1% (v/v) Triton X-100, 0.1 mg/ml bovine serum albumin (BSA)] (Thermo Fisher 
Scientific Inc), 10 pmol of each primer (Integrated DNA Technologies), magnesium sulphate 
(MgSO4) (indicated in Tables 2.1 to 2.3) (Thermo Fisher Scientific Inc), betaine solution 
(indicated in Tables 2.1 to 2.3) (Sigma-Aldrich), 0.1 mM of each 2‟-deoxynucleotide (dNTP) 
(dATP, dCTP, dGTP, dTTP) (Thermo Fisher Scientific Inc), 0.25 units (U) Taq polymerase 
(Thermo Fisher Scientific Inc) and 0.25 U Pfu polymerase (Thermo Fisher Scientific Inc). 
Each 25 μl Taq enzyme reaction from Thermo Fisher Scientific contained 50 ng of DNA, 1 X 
Taq-buffer [75 mM Tris-HCL, 20 mM (NH4)2SO4, 0.01% (v/v) Tween 20] (Thermo Fisher 
Scientific Inc), 10 pmol of each primer (Integrated DNA Technologies), magnesium chloride 
(MgCl2) (indicated in Tables 2.1 to 2.3) (Thermo Fisher Scientific Inc), betaine solution 
(indicated in Tables 2.1 to 2.3) (Sigma-Aldrich), 0.1 mM of each dNTP (dATP, dCTP, dGTP, 
dTTP) (Thermo Fisher Scientific Inc) and 0.5 units (U) Taq polymerase (Thermo Fisher 
Scientific Inc). 
Each 25 μl Taq enzyme from KAPABiosystems reaction contained 50 ng of DNA, 1 X 
KAPA HiFi HotStart ReadyMix buffer (25 mM Mg
2+
) (KAPABiosystems), 10 pmol of each 
primer (Integrated DNA Technologies), betaine solution (indicated in Table 2.1, Table 2.2 
and Table 2.3) (Sigma-Aldrich) and 0.5 units of high fidelity Taq enzyme 
(KAPABiosystems). 
The cycles used for amplification are described below. 
Cycle A: An initial denaturation step was performed at 95°C for 5 minutes, followed by 15 
cycles of denaturation at 95°C for 30 seconds, annealing at the temperature (first TA) given in 
Table 2.1 for 45 seconds, and elongation at 72ºC for 30 seconds. This was followed by 20 
cycles of denaturation at 95°C for 30 seconds, annealing at the temperature (second TA) given 
in Table 2.1 for 45 seconds, and elongation at 72ºC for 30 seconds. A final elongation step at 
72°C for 10 minutes was performed and then the sample was stored at 4ºC. 
Cycle B: An initial denaturation step was performed at 95°C for 5 minutes. Following this, 
35 cycles of denaturation at 95°C for 30 seconds, annealing at the temperature (TA) given in 
Table 2.1 for 1 minute and elongation at 72°C for 2 minutes were performed. Thereafter, a 
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final elongation step at 72°C for 10 minutes was performed and then the sample was stored at 
4ºC. 
Cycle C: An initial denaturation step was performed at 95°C for 5 minutes. Thereafter, 35 
cycles of denaturation at 95°C for 30 seconds, annealing at the temperature (TA) given in 
Table 2.1 for 30 seconds and elongation at 72°C for 2 minutes were performed. Following 
this, a final elongation step at 72°C for 10 minutes was performed and then the sample was 
stored at 4ºC. 
Cycle D: An initial denaturation step was performed at 95°C for 2 minutes. Thereafter, 35 
cycles of denaturation at 98°C for 20 seconds, annealing at the temperature (TA) given in 
Table 2.1 for 15 seconds and elongation at 72°C for 2 minutes were performed. Thereafter, a 
final elongation step at 72°C for 5 minutes was performed and then the sample was stored at 
4ºC. 
Cycle E: An initial denaturation step was performed at 95°C for 5 minutes. Thereafter, 35 
cycles of denaturation at 95°C for 30 seconds, annealing at the temperature (TA) given in 
Table 2.1 for 45 seconds and elongation at 72°C for 30 seconds were performed. Following 
this, a final elongation step at 72°C for 10 minutes was performed and then the sample was 
stored at 4ºC. 
Cycle F: An initial denaturation step was performed at 95°C for 5 minutes. Thereafter, 40 
cycles of denaturation at 95°C for 30 seconds, annealing at the temperature (TA) given in 
Table 2.1 for 45 seconds and elongation at 72°C for 30 seconds were performed. Following 
this, a final elongation step at 72°C for 10 minutes was performed and then the sample was 
stored at 4ºC. 
Cycle D is specific to the Taq enzyme from KAPA Biosystems. The specific enzymes used 
are indicated in Tables 2.1 to 2.3 (as described in the Key to the Tables). 
 
2.2.3 Agarose Gel Electrophoresis 
A 2% (w/v) agarose gel consisting of 1X TBE buffer [90 mM Tris (C4H11NO3), 90 mM boric 
acid (H3BO3), 1mM EDTA (C10H14N2Na2O8.2H20)] and stained with 0.01% (v/v) ethidium 
bromide (EtBr) was used to visualise PCR fragments smaller than 1 000 bp. For PCR 
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fragments larger than 1 000 bp, a 0.8% (w/v) agarose gel was utilised. Five µl of cresol red 
loading buffer [0.02% (w/v) cresol red, 0.34% (w/v) sucrose] was loaded with 5 µl of PCR 
sample in each well. A 3% (w/v) agarose gel was used to separate RFLP analysed samples. 
Ten µl of cresol red loading buffer was added directly to the RFLP sample from which 15 µl 
of the sample-cresol red mixture was loaded in each well. The 100 bp O‟GeneRuler (Thermo 
Fisher Scientific Inc) was used as a molecular ladder for comparison for fragments smaller 
than 1 000 bp. For fragments larger than 1 000 bp, the 1 kb GeneRuler (Thermo Fisher 
Scientific Inc) was used for size comparison. A sample of 2.5 µl of the size standard was 
electrophoresed with each run of the PCR and RFLP products to determine the size of the 
products. The electrophoresis was performed for between 45 and 120 minutes at 120 V in 1X 
TBE buffer. Ultraviolet (UV) light transillumination was used to visualise the 
electrophoresed PCR products using the Multigenius Bio Imaging System (Syngene). 
 
2.3 MUTATION DETECTION 
2.3.1 Semi-automated bi-directional DNA sequencing analysis 
In order to determine whether any known and/or novel variants exist in the promoter region 
of the five genes under investigation, it was necessary to undertake an exploratory screening 
of this region. Fifteen samples were randomly selected from the patient group and subjected 
to semi-automated bi-directional sequencing analysis. All sequencing was performed using 
the Applied Biosystems 3730xl DNA Analyzer. The resulting chromatograms were compared 
to the reference sequence for each gene obtained from the Ensembl website (Hubbard et al., 
2007; www.ensembl.org). This comparison was performed using the program Bioedit 
Sequence Alignment Editor version 7.0.9.0 (Hall, 1999) and variants were subsequently 
identified.  
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Figure 2.1 Work flow for the identification and subsequent genotyping of variants. A random subset of samples was initially 
submitted to semi-automated bi-directional sequencing analysis to perform an exploratory screen for known and/or novel 
variants. The results from the exploratory screen were used to design mutation detection analyses based on the distance 
between variants, and then whether the variants were situated within an RE recognition site. 
 
Sequencing data were available for the control group used for comparison to the CYBRD1 
promoter region but a second program, FinchTV version 1.4.0 (www.geospize.com), had to 
be used to visualise the chromatograms. The screened region for each gene, all primers used 
and the identified variants are provided in Addendum A. 
Once the presence of variants was confirmed they were named and subsequently verified 
using the dbSNP (Sherry et al., 2011; http://www.ncbi.nlm.nih.gov/projects/SNP) database to 
determine whether the variant was known and/or novel. The HapMap (The International 
HapMap Consortium, 2003; www.hapmap.org) database was utilised to determine genotype 
and allele frequencies identified within different regions and was thus used as a comparison 
to genotype and allele frequencies found in this study. In instances where HapMap either did 
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not recognise a variant or did not have frequency data available for a variant, the dbSNP 
population diversity data was used for comparison. Based on the variants discovered using 
this method, the remaining patient and control samples were genotyped using either RFLP, 
HEX-SSCP or semi-automated bi-directional sequencing analysis (as indicated in Tables 2.2 
and 2.3). 
The CYBRD1 and SLC40A1 genes presented either a large number of variants or variants that 
are in close proximity to one another. This makes genotyping through RFLP or HEX-SSCP 
analysis difficult and so the remaining samples were genotyped by subjecting the entire 
promoter of CYBRD1 (encompassing 20 variants) and a portion of the promoter of SLC40A1 
(encompassing 5 variants) to semi-automated bi-directional sequencing analysis. The variants 
of the SLC40A1 promoter not encompassed by the sequencing reaction were genotyped by 
HEX-SSCP analysis in the remaining patient and control samples. Chromatograms of all 
variants are provided in Addendum B. 
 
2.3.2 Restriction Fragment Length Polymorphism (RFLP) Analysis 
The tool NEBcutter version 2.0 (Vincze et al., 2003; tools.neb.com/NEBcutter2/) was used to 
determine if any of the identified variants were located within a restriction endonuclease (RE) 
recognition site and thus whether the variant could be genotyped for the remaining samples 
using RFLP analysis. Three variants (-582 A/G [HAMP]; -561 A/G, -467 G/C [HFE]) were 
situated within RE sites and were subsequently subjected to RFLP analysis. Variant -582 A/G 
in the promoter region of the HAMP gene contained a recognition site for the enzyme BstUI 
and the enzyme would only digest the DNA fragment in the presence of the variant. Each 
20 µl reaction consisted of 10 µl of PCR product (previously amplified under the conditions 
as described in Table 2.2), 1 X Green buffer (50 mM potassium acetate [KCH3CO2], 20 mM 
tris-acetate [C4H11NO3], 10 mM magnesium acetate [Mg(CH3CO2)2], 100 µg/ml BSA, pH 7.9 
at 25ºC) (New England Biolabs Inc.) and 2 units of BstUI (New England Biolabs Inc.). The 
reaction mixture was digested at 60ºC for 16 hours following which it was electrophoresed on 
a 3% (w/v) agarose gel as described in section 2.2.3. 
Variant -561 A/G in the promoter region of the HFE gene contained a recognition site for the 
enzyme BsrBI and the enzyme would only digest the DNA fragment in the presence of the 
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variant. Each 20 µl reaction consisted of 10 µl of PCR product (previously amplified under 
the conditions as described in Table 2.2), 1 X Green buffer (50 mM KCH3CO2, 20 mM 
C4H11NO3, 10 mM Mg(CH3CO2)2, 100 µg/ml BSA, pH 7.9 at 25ºC) (New England Biolabs 
Inc.) and 4 units of BsrBI (New England Biolabs Inc.). The reaction mixture was digested at 
37ºC for 16 hours and then the enzyme was heat inactivated at 80ºC for 20 minutes. The 
reaction was electrophoresed on a 3% (w/v) agarose gel as described in section 2.2.3. 
Variant -467 G/C in the promoter region of the HFE gene contained a recognition site for the 
enzyme AflIII and the enzyme is expected to only digest the DNA fragment in the presence 
of the variant. Each 20 µl reaction consisted of 10 µl of PCR product (previously amplified 
under the conditions as described in Table 2.2), 1 X Green buffer (100 mM NaCl, 50 mM 
tris-HCL, 10 mM MgCl2, 100 µg/ml BSA, pH 7.9 at 25ºC) (New England Biolabs Inc.), 1% 
BSA and 2 units of AflIII (New England Biolabs Inc.). The reaction mixture was digested at 
37ºC for 16 hours and then the enzyme was heat inactivated at 80ºC for 20 minutes. The 
reaction was electrophoresed on a 3% (w/v) agarose gel as described in section 2.2.3. Gel 
images of RFLP analyses are provided in Addendum B. 
 
2.3.3 Heteroduplex Single-Strand Conformation Polymorphism (HEX-SSCP) Analysis 
PCR products that were not genotyped using semi-automated bi-directional sequencing 
analysis were electrophoresed on HEX-SSCP gels using the technique described by Kotze et 
al. (1995). All gels were electrophoresed using the Hoefer vertical gel apparatus. Each PAA 
gel was supplemented with urea and consisted of 12% (w/v) PAA [1%C of 40% stock (99 
acrylamide (AA): 1 bisacrylamide (BAA))], 7.5% (w/v) urea, 1.5 X TBE buffer, 0.1% (w/v) 
ammonium persulphate (APS), and 0.1% (v/v) tertamethylethylenediamine (TEMED). 
Prior to gel loading, 15 µl of loading dye [95% (v/v) formamide, 20mM EDTA, 0.05% (v/v) 
bromophenol blue, 0.05% (v/v) Xylene cyanol] was added to each PCR product and this 
solution was denatured at 95ºC for 10 minutes and subsequently placed directly onto ice. 
20 µl of each denatured product was loaded into a separate well of a gel using a Microlitre™ 
syringe (Hamilton). All loaded gels were subjected to electrophoresis at 250 volts for 
± 18 hours (overnight). PAA gels supplemented with urea were electrophoresed at 4ºC while 
PAA gels supplemented with glycerol were electrophoresed at room temperature. Samples 
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that had been previously genotyped via semi-automated bi-directional sequencing analysis 
were electrophoresed alongside the genotyping samples in order to provide comparisons. Any 
samples that could not be identified through comparison to the sequenced sample were 
subjected to semi-automated bi-directional sequencing analysis to confirm the presence of 
variants. All gels were visualised by being subjected to UV transillumination using the 
MULTI-GENIUS Bio-Imaging System (Syngene). 
Gel images of HEX-SSCP analyses are provided in Addendum B. 
 
2.5 IN SILICO ANALYSES 
In silico analyses were performed on variants identified in the promoter region of the five 
iron genes under investigation. This was done in order to determine if these variants had any 
effect on putative TFBSs that occurred in these regions. This allows one to determine 
whether any putative TFBSs are abolished or created due to a specific variant and thus 
hypothesise the effect of the specific variant(s) on gene expression.  
The programs ALIBABA2 (version 2.1), TFBlast (version 0.1) and PROMO (version 1.0) 
from TRANSFAC®7 were used to perform in silico analyses (Wingender et al., 2001; 
http://gene-regulation.com/pub/database.html#transfac). These programs screen an input 
sequence for putative TFBSs found in the TRANSFAC®7 database. Both a graphical and 
text output are created giving the position and type of TFBS throughout the input sequence. 
Comparing the outputs from the wild type sequence to those of each variant allows for the 
determination of any changes to the TFBS composition in the sequence due to the presence or 
absence of the variant. 
 
2.6 STATISTICAL ANALYSIS 
2.6.1 Iron parameters 
Descriptive statistics were performed on the iron parameter data using Excel (2007). For 
normally distributed data parametric tests were performed as follows: F-tests were performed 
Stellenbosch University http://scholar.sun.ac.za
  Chapter 2: Detailed Experimental Procedures 
 
  
42 
 
on the data and if a P-value of less than 0.05 was returned, the data were subsequently 
subjected to an unpaired t-test assuming unequal variances. If the F-test returned a P-value of 
greater than 0.05 the data were subsequently subjected to an unpaired t-test assuming equal 
variances. The F- and t-tests were performed for each iron parameter to determine the 
variance between the patient and control groups. For non-normally distributed data a non-
parametric test, the Mann-Whitney test, was performed to compare the data. The F-tests, 
unpaired t-tests and Mann-Whitney tests were performed using the GraphPad Prism™ 
statistical package software (version 5.00) (GraphPad Software, San Diego, CA) 
(www.graphpad.com). The Pearson r correlation test was performed on GraphPad Prism™ 
with graph outputs being created in Excel to compare each iron parameter to another to 
determine if any relationship exists between them. These correlations were performed for the 
entire cohort, as well as within the patient and control groups. 
For each variant, the data was further divided into two groups; 1) individuals without the 
presence of the variant (wild type individuals), and, 2) individuals with the presence of the 
variant (individuals that were either heterozygous or homozygous for the variant). The iron 
parameters were compared for these new groupings to determine whether the presence of a 
variant had any effect on a specific iron parameter. Parametric and non-parametric tests were 
performed on this data as described above. 
 
2.6.2 Genotyping 
Version 1.3 of the program Tools for Population Genetics Analysis (TFPGA) [Miller, 1997] 
was used to determine the genotype and allele frequencies for all variants discovered and this 
program performed the chi-squared and Fisher‟s exact tests to determine whether the data for 
each group are in Hardy-Weinberg Equilibrium (HWE). The chi-squared test was used in 
instances where all genotypes had an observed number of more than 5. Fisher‟s exact test was 
used in cases where a genotype had less than, or equal to, 5 observed individuals. The Exact 
test was also used to determine whether the allele frequencies differed statistically 
significantly between the patient and control groups for each identified variant. TFPGA does 
not offer an Exact test to compare genotype frequencies and so the program Genepop 
(version 4.2.1) was used (Rousset, 2008). 
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2.6.3 TB association 
Correlation studies were performed in order to determine whether any relationship exists 
between the iron parameters measured, genotype and susceptibility to M. tuberculosis 
infection. 
Stellenbosch University http://scholar.sun.ac.za
  Chapter 3: Results & Discussion 
 
44 
 
 
 
 
 
 
Chapter 3 
 
RESULTS AND DISCUSSION 
  
Stellenbosch University http://scholar.sun.ac.za
  Chapter 3: Results & Discussion 
 
45 
 
3. RESULTS & DISCUSSION 
3.1 ABSTRACT 
Tuberculosis (TB) is a serious epidemic in South Africa and many other countries worldwide. 
Due to the increasing need for more effective treatment regimes and preventative measures 
the necessity for further study of the interaction between M. tuberculosis and the host system 
has become of paramount importance. Iron metabolism plays a significant role in the 
development of TB as the causative agent, Mycobacterium tuberculosis, requires iron from 
the host reticuloendothelial macrophages in order to proliferate. It is for this reason that the 
regulation of iron in the body is crucial and thus the regulation of the genes that regulate the 
iron metabolism pathway is of paramount importance. One of the mechanisms of controlling 
the expression of these genes is through transcriptional regulation and therefore the promoter 
region of genes have been targeted. Five genes were chosen – CYBRD1, HAMP, HFE, LTF 
and SLC40A1 – for investigation as to the role they play in M. tuberculosis susceptibility. 
The study cohort consisted of 49 TB patients and 51 healthy, unrelated, randomly selected 
controls all of whom were Black, Xhosa-speaking individuals. The control group was further 
divided into two groups: the first group consisted of 22 individuals which were used for 
comparison to the promoter region of the CYBRD1 gene, which did not have iron parameter 
data available; and a second group containing 29 individuals used for analyses of the four 
remaining genes, which had iron parameter data available. The promoter region of these 
genes were screened for both known and/or novel variants. In order to assess whether any 
variants exist within this region, 15 randomly selected patient samples were screened using 
Polymerase Chain Reaction (PCR) amplification followed by semi-automated bi-directional 
sequencing. From the initial screening of the first 15 sequenced samples a total of 40 variants 
were found in the promoter region of the 5 genes under investigation. Of these 40 variants 30 
were found to be previously described while 10 variants were novel. Due to technical 
difficulties, only 31 variants were genotyped for the remainder of the patient and control 
groups. 
Of the 31 variants subjected to mutation detection analyses, 11 variants (-1849 T/G, -1844 
C/G, -1813 C/T, -1749 del(T)6G, -1477 G/A, -1459 T/C, -1346 T/C, -1272 T/C, -238 A/G, -
166 C/G [CYBRD1]; -561 A/G [HFE]) demonstrated a statistically significant difference 
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when comparing allele frequencies between the patient and control groups. Ten of these 
variants (-1849 T/G, -1813 C/T, -1749 del(T)6G, -1477 G/A, -1459 T/C, -1346 T/C, -1272 
T/C, -238 A/G, -166 C/G [CYBRD1]; -561 A/G [HFE]) demonstrated a statistically 
significant difference when comparing genotype frequencies between the two groups. The 
influence of a variant on the iron parameters was determined through the use of the unpaired 
t-test for those genes that had iron parameter data available (HAMP, HFE, SLC40A1). The 
results showed that a statistically significant difference exists for 3 (-1470 C/T [HFE]; -1355 
G/C, -1098 G/A [SLC40A1]) of the 11 variants compared. A Pearson r correlation test was 
performed to determine if any correlations exist between iron parameters within the cohort as 
a whole, and within each group separately. A strong positive correlation was demonstrated 
with serum iron and transferrin saturation levels within both the groups separately as well as 
when compared in the entire cohort. Interestingly, a statistically significant negative 
correlation was observed between serum ferritin and serum transferrin levels in the patient 
group exclusively which could suggest the possible influence of these proteins and their 
encoding genes on M. tuberculosis susceptibility. 
In silico analyses revealed a number of putative transcription factor binding sites (TFBSs) in 
the promoter region of the five genes under investigation. It was predicted that the presence 
of specific variants caused either the abolishment or creation of a total of 41 TFBSs. The 
elimination or addition of TFBSs may potentially cause changes in the regulation of the 
affected gene. 
The results from this study indicate the possible implication of some of the variants 
discovered in increasing iron absorption which may induce increased pathogenic infection. 
From the obtained results it is clear that further investigation is required as to the exact 
mechanism by which iron, the iron pathway, and the genes involved in this pathway are 
associated with M. tuberculosis susceptibility. 
 
3.2 INTRODUCTION 
One in every 3 individuals in the world is reported to be infected with M. tuberculosis but 
only 10% of these individuals will ever develop the active disease (Dye et al., 1999; Herzog, 
1998). The high prevalence of this low penetrating disease could possibly be attributed to a 
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number of factors influencing susceptibility. Some of the factors known to affect 
susceptibility in a minority of occurrences include: alcohol abuse, diabetes, corticosteroid 
use, HIV infection, and old age (Bellamy et al., 2000). However, the remaining cases are 
affected by the intricate interaction between genetic and environmental factors which lead to 
the development of active TB. The influence of genetic factors in M. tuberculosis 
susceptibility has been implicated by the discovery of racial differences and through the use 
of twin studies (Bellamy et al., 2000; Lipsitch & Sousa, 2002; Comstock, 1978). 
M. tuberculosis requires a plethora of nutrients from its host during infection and of these, 
iron has been shown to be vital for its growth and proliferation (Cole et al., 1998); this has 
necessitated the development of methods for outcompeting its host for iron (Olakanmi et al., 
2007). For this reason iron metabolism and the genes involved are gaining increasing 
popularity in research in terms of their possible connection to M. tuberculosis susceptibility. 
Iron is not only important for bacterial proliferation but is crucial for the survival and 
proliferation of cells, where it acts as both an electron acceptor and donor in many important 
redox reactions (Ong et al., 2006). The CYBRD1 gene produces the protein DCYTB which 
functions as a ferrireductase reducing Fe
3+
 to Fe
2+
 in order for iron absorption to occur into 
duodenal enterocytes (McKie et al., 2001). The HAMP gene encodes for the protein product 
hepcidin which has some antimicrobial activity but mainly functions by binding to FPN and 
subsequently causing its internalization and degradation therefore decreasing iron efflux from 
cells (Collins, 2008). The haemochromatosis protein, encoded by the HFE gene, regulates 
absorption of iron by binding to TFR thereby decreasing its affinity for TF (Nandar & 
Connor, 2011). This interaction leads to the decreased interaction of TF with the cell 
membrane which in turn leads to less iron being absorbed by the cell from TF. The LTF gene 
encodes for the protein lactotransferrin which is responsible for transportation of iron in the 
body (Olakanmi et al., 2007). This protein is found mainly at mucosal membranes such as in 
the lungs and has been shown to have some antimicrobial activity (Orsi, 2004). The only 
known iron export protein to date is FPN which is encoded by the SLC40A1 gene which 
regulates the efflux of iron from cells (Collins, 2008). 
Since these genes and their products play an integral role in iron metabolism and potentially 
M. tuberculosis susceptibility it is important to understand the mechanisms by which they are 
regulated. The aim of this study is thus to elucidate the effect of 5 genes – CYBRD1, HAMP, 
HFE, LTF and SLC40A1 – involved in iron metabolism on M. tuberculosis susceptibility. 
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3.3 MATERIALS AND METHODS 
Ethical approval was granted for this study from the Research and Ethics/Biosafety 
Committee, Faculty of Health Sciences, University of Stellenbosch (N10/06/194). The reader 
is referred to Chapter 2 of this thesis for the detailed experimental procedures performed. 
 
3.4 RESULTS 
3.4.1 Mutation Detection 
3.4.1.1 Variant List 
The promoter region of 5 genes (CYBRD1, HAMP, HFE, LTF and SLC40A1) known to play a 
role in the metabolism of iron were screened in an initial sample subset as an exploratory 
venture to determine the presence of known and/or novel variants in this region. The sample 
subset consisted of 15 randomly selected patient samples. This initial screening yielded a 
total of 40 variants of which 10 were shown to be novel. Both the remainder of the patient 
group and the control group were subsequently screened for the variants through either semi-
automated bi-directional sequencing, HEX-SSCP or RFLP analysis (as described in Tables 
2.2 and 2.3). 
If variants were closely spaced, e.g., the variants found in the promoter region of CYBRD1 
(Addendum A), then semi-automated bi-directional sequencing analysis was used as the 
method to detect genotypes. This method was employed for all variants discovered in the 
promoter region of the CYBRD1 gene, and for 5 variants in the promoter region of SLC40A1 
(Tables 2.2 and 2.3). The chromatograms of all 40 variants are provided in Addendum B. 
For those variants that were not as closely spaced – where a primer could be placed between 
variants for amplification of separate fragments containing only one variant – either HEX-
SSCP or RFLP analysis was employed as the technique used to genotype the variant. Each 
variant was examined to determine whether it was suitable for RFLP analysis (whether it was 
situated in a RE recognition site), and if proven suitable it was genotyped using the enzyme 
most apt for its digestion (gel images are provided in Addendum B). In most cases, the 
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variants were not suitable for RFLP analysis and as such were genotyped using HEX-SSCP 
analysis. 
In the promoter region of the genes investigated, the following variants were identified; 
CYBRD1: 16 previously described variants (-1849 T/G, -1844 C/G, -1813 C/T, -1749 del 
(T)6G, -1540 G/A, -1477 G/A, -1459 T/C, -1346 T/C, -1272 T/C, -1011 T/A, -627 T/C, -624 
G/A, -449 C/G, -399 T/G, -238 A/G, -166 C/G) and four novel variants (-849 C/G, -492 A/G, 
-454 C/T, -397 A/C); HAMP: three previously described variants (-1631 C/T, -582 A/G, -188 
C/T) and one novel variant (-323 C/T); HFE: two previously described variants (-1168 A/G, -
467 G/C) and two novel variants (-561 A/G, -331 A/C); LTF: one previously described 
variant (-746 del [AAA]/ins [AA]) and three novel variants (-1377 T/G, -457 T/C, -437 C/G); 
and SLC40A1: eight previously described variants (-1470 C/T, -1461 T/C, -1399 G/A, -1355 
G/A, -1098 G/A, -750 G/A, -662 C/T, -501 T/C). These variants are listed in Table 3.1 which 
also indicates which variants were excluded, the motivation for exclusion, allele frequency of 
the variant in both the patient and control groups, and the results of the HWE analysis. 
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Table 3.1 General information regarding variants, including HWE analysis 
Gene 
Nucleotide 
position and 
change 
Reference 
sequence 
number 
Included/ 
Excluded from 
further analyses 
Motivation for exclusion 
Variant allele 
frequency 
HWE analyses 
Patients Controls 
Patients Controls 
n carriers 
out of total 
P-value 
n carriers 
out of total 
P-value 
CYBRD1 
-1849 T/G rs12692964 Included  0.26 0.06 15/42 0.00 1/18 0.03 
-1844 C/G rs7585974 Included  0.92 0.75 41/42 0.24 15/18 0.03 
-1813 C/T rs12692965 Included  0.31 0.06 18/43 0.00 1/18 0.03 
-1749 del (T)6G rs140246632 Included  0.69 0.39 39/43 1.00 9/18 0.04 
-1540 G/A rs67339714 Included  0.26 0.11 19/43 1.00 2/18 0.00 
-1477 G/A rs66572658 Included  0.31 0.06 11/43 0.21 1/18 0.03 
-1459 T/C rs10199858 Included  0.70 0.39 39/43 1.00 7/18 0.00 
-1346 T/C rs66818940 Included  0.35 0.06 21/43 0.01 1/18 0.03 
-1272 T/C rs62183550 Included  0.20 0.44 15/43 0.65 9/18 0.00 
-1011 T/A rs12621138 Included  0.24 0.26 13/39 0.00 9/21 0.58 
-849 C/G  Included  0.39 0.40 27/47 0.10 18/30 0.36 
-627 T/C rs10200648 Included  0.09 0.05 6/47 0.02 3/30 1.00 
-624 G/A rs884408 Included  0.12 0.18 9/47 0.10 8/30 0.03 
-492 A/G  Included  0.15 0.12 14/47 0.57 6/30 0.33 
-454 C/T  Included  0.04 0.00 2/47 0.00 0/30 - 
-449 C/G rs112362682 Included  0.02 0.02 1/47 0.01 1/30 1.00 
-399 T/G rs884409 Included  0.13 0.10 7/47 0.00 5/30 0.24 
-397 A/C  Included  0.14 0.05 13/47 0.57 3/30 1.00 
-238 A/G rs868106 Included  0.83 0.53 45/47 0.60 18/29 0.00 
-166 C/G rs2356782 Included  0.64 0.23 28/43 0.00 8/28 0.00 
          
HAMP 
-1631 C/T rs66868858 Included  0.28 0.31 25/48 0.30 13/27 0.37 
-582 A/G rs10421768 Included  0.18 0.16 17/49 1.00 8/29 0.52 
-323 C/T  Included  0.01 0.00 1/49 1.00 0/29 - 
-188 C/T rs116178041 Excluded Could not amplify all samples successfully      
          
HFE 
-1168 A/G rs62625311 Included  0.08 0.04 13/49 1.00 9/28 1.00 
-561 A/G  Included  0.39 0.18 34/45 0.00 8/22 1.00 
-467 G/C rs2794720 Included  0.15 0.20 8/49 0.29 2/24 0.25 
-331 A/C  Excluded Genotypes indistinguishable on HEX-SSCP gels      
          
LTF 
-1377 T/G  Excluded Genotypes indistinguishable on HEX-SSCP gels      
-746 
delAAA/insAA 
rs5848800 Excluded Genotypes indistinguishable on HEX-SSCP gels      
-457 T/C  Excluded All samples were homozygous for the variant      
-437 C/G  Excluded Genotypes indistinguishable on HEX-SSCP gels      
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Table 3.1 continued 
Gene 
Nucleotide 
position and 
change 
Reference 
sequence 
number 
Included/ 
Excluded from 
further analyses 
Motivation for exclusion 
Variant allele 
frequency 
HWE analyses 
Patients Controls 
Patients Controls 
n carriers 
out of total 
P-value 
n carriers 
out of total 
P-value 
SLC40A1 
-1470 C/T rs16831699 Included  0.06 0.05 6/49 1.00 1/21 1.00 
-1461 T/C rs77227487 Included  0.18 0.12 14/49 0.04 3/21 0.01 
-1399 G/A rs79516140 Included  0.05 0.14 3/49 0.00 3/21 0.00 
-1355 G/C rs3811621 Included  0.52 0.64 30/49 0.19 18/21 1.00 
-1098 G/A rs10202029 Included  0.27 0.12 24/49 0.47 5/21 1.00 
-750 G/A rs13015236 Excluded Genotypes indistinguishable on HEX-SSCP gels      
-662 C/T rs12693542 Excluded Could not optimise genotyping fragment      
-501 T/C rs6728200 Excluded Could not optimise genotyping fragment      
P ≤ 0.05 considered to be statistically significant (highlighted in red). Abbreviations: - = no calculation performed (only wild type individuals in group); A = adenine; C = 
cytosine; CYBRD1 = cytochrome B reductase 1 gene; del = deletion; G = guanine; HAMP = hepcidin antimicrobial peptide gene; HFE = Haemochromatosis gene; HWE = 
Hardy-Weinberg equilibrium; ins = insertion; n carriers out of total = number of individuals carrying the variant allele (either heterozygote or homozygote) out of the total 
number of individuals genotyped for that locus; P = probability; rs = reference sequence; SLC40A1 = solute carrier family 40 member A1 gene; T = thymine 
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As shown in Table 3.1, nine of the 40 variants were excluded from further analysis. The 
promoter region of the LTF gene proved difficult to amplify. The close proximity of the 
variants warranted genotyping by semi-automated bi-directional sequencing as indicated in 
section 2.3.1 but a larger fragment encompassing all four variants proved impossible to 
amplify for all samples. It was then decided to amplify smaller fragments spanning one 
variant each in order to genotype the variants using conventional methods such as RFLP and 
HEX-SSCP analysis. However, the genotyping was complicated by the inability to 
distinguish individual genotypes by these conventional methods. The variant -746 
delAAA/insAA proved particularly difficult to genotype since the combination of both a 
deletion and insertion at the same site produced a number of varying genotypes which were 
indistinguishable on HEX-SSCP gels. For these reasons the promoter region of the LTF gene 
was excluded from further analyses. The novel variant -457 T/C produced only homozygote 
individuals, which while interesting, does not allow for analysis through the means employed 
by this study. 
A number of other variants proved difficult to amplify and genotype and were subsequently 
also excluded from further analyses. These promoter region variants include: rs116178041 in 
the HAMP gene; the novel variant -331 A/C in the HFE gene; and variants rs13015236, 
rs12693542 and rs6728200 in the SLC40A1 gene (as described in Table 3.1). 
 
3.4.1.2 HWE Analysis 
HWE analyses were performed in TFPGA using the default settings for the exact and the chi-
squared tests. Table 3.1 shows the probability (P) values obtained. All statistically significant 
results (P < 0.05) have been highlighted in red. For CYBRD1 the results indicate that 8 of the 
20 variants are not in HWE for the patient group; and 12 of the 20 variants are not in HWE 
for the control group. For HAMP all variants were in HWE except for the variant -323 C/T in 
the control group where the calculation could not be performed as only wild type individuals 
were seen. For HFE the variant -561 A/G was the only variant to deviate from HWE and this 
deviation was seen for the patient group but not in the control group. For SLC40A1 the 
variants -1461 T/C and -1399 G/A were found to deviate from HWE in both the patient and 
control groups. 
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3.4.1.3 Genotype and Allele Frequency Analysis 
Table 3.2 shows the calculated genotype and allele frequencies for all genotyped variants as 
well as the results of the Exact test. The Exact test was used to determine whether there was a 
statistically significant difference in allele and genotype frequencies when comparing the 
patient to the control group for every identified variant. The Exact test for genotypic 
population differentiation was performed using Genepop whereas the allelic population 
differentiation was determined using TFPGA. The default settings for the Exact test were 
used in both programs.  
Of the 31 variants subjected to the Exact test for both allele and genotype population 
differentiation, 11 showed statistically significant differences in allele frequencies between 
the patient and control groups, and 10 of these variants showed statistically significant 
differences in genotype frequencies as well. Some variants were shown to be marginally 
statistically significant when comparing the genotype and allele frequencies. However, for 
the purpose of this study only those variants which showed a statistically significant 
difference were subjected to in silico analyses to determine whether any putative TFBSs were 
created or abolished by the presence or absence of these variants.  
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Table 3.2 Genotype and allele frequencies for variants identified 
CYBRD1 (ENSG0000007196) 
Nucleotide position 
and change 
Ancestral allele 
(dbSNP) 
Group n Genotype Frequency 
P-value 
(Genepop) 
2n Allele Frequency 
P-value 
(TFPGA) 
-1849 T/G 
rs12692964 
T 
  TT TG GG   T G  
Patients 42 0.64 0.19 0.17 
0.03 
84 0.74 0.26 
0.01 
Controls 18 0.94 0.00 0.06 36 0.94 0.06 
          
-1844 C/G 
rs7585974 
G 
  CC CG GG   C G  
Patients 42 0.02 0.12 0.86 
0.08 
84 0.08 0.92 
0.02 
Controls 18 0.17 0.17 0.66 36 0.25 0.75 
          
-1813 C/T 
rs12692965 
C 
  CC CT TT   C T  
Patients 43 0.58 0.21 0.21 
0.01 
86 0.69 0.31 
0.01 
Controls 18 0.94 0.00 0.06 36 0.94 0.06 
          
-1749 del (T)6G 
rs104246632 
NID 
  WT HET HOM   WT del(T)6G  
Patients 43 0.09 0.44 0.47 
0.01 
86 0.31 0.69 
0.00 
Controls 18 0.50 0.22 0.28 36 0.61 0.39 
          
-1540 G/A 
rs67339714 
G 
  GG GA AA   G A  
Patients 43 0.56 0.37 0.07 
0.13 
86 0.74 0.26 
0.09 
Controls 18 0.89 0.00 0.11 36 0.89 0.11 
          
-1477 G/A 
rs66572658 
G 
  GG GA AA   G A  
Patients 43 0.51 0.35 0.14 
0.01 
86 0.69 0.31 
0.00 
Controls 18 0.94 0.00 0.06 36 0.94 0.06 
          
-1459 T/C 
rs10199858 
C 
  TT TC CC   T C  
Patients 43 0.09 0.42 0.49 
0.01 
86 0.30 0.70 
0.00 
Controls 18 0.61 0.00 0.39 36 0.61 0.39 
          
-1346 T/C 
rs66818940 
C 
  TT TC CC   T C  
Patients 43 0.51 0.28 0.21 
0.00 
86 0.65 0.35 
0.00 
Controls 18 0.94 0.00 0.06 36 0.94 0.06 
          
-1272 T/C 
rs62183550 
T 
  TT TC CC   T C  
Patients 43 0.65 0.30 0.05 
0.02 
86 0.80 0.20 
0.01 
Controls 18 0.50 0.11 0.39 36 0.56 0.44 
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Table 3.2 continued 
CYBRD1 (ENSG0000007196) 
Nucleotide position 
and change 
Ancestral allele 
(dbSNP) 
Group n Genotype Frequency 
P-value 
(Genepop) 
2n Allele Frequency 
P-value 
(TFPGA) 
-1011 T/A 
rs12621138 
T 
  TT TA AA 
1.00 
 T A 
0.83 
Patients 39 0.67 0.18 0.15 78 0.76 0.24 
Controls 21 0.57 0.33 0.10 42 0.74 0.26 
        
-849 C/G 
This study 
NID 
  CC CG GG 
1.00 
 C G 
1.00 
Patients 47 0.43 0.36 0.21 94 0.61 0.39 
Controls 30 0.40 0.40 0.20 60 0.60 0.40 
        
-627 T/C 
rs10200648 
T 
  TT TC CC 
0.59 
 T C 
0.53 
Patients 47 0.87 0.09 0.04 94 0.91 0.09 
Controls 30 0.90 0.10 0.00 60 0.95 0.05 
        
-624 G/A 
rs884408 
G 
  GG GA AA 
0.42 
 G A 
0.35 
Patients 47 0.81 0.15 0.04 94 0.88 0.12 
Controls 30 0.73 0.17 0.10 60 0.82 0.18 
        
-492 A/G 
This study 
NID 
  AA AG GG 
0.63 
 A G 
0.63 
Patients 47 0.70 0.30 0.00 94 0.85 0.15 
Controls 30 0.80 0.17 0.03 60 0.88 0.12 
        
-454 C/T 
This study 
NID 
  CC CT TT 
0.52 
 C T 
0.16 
Patients 47 0.96 0.00 0.04 94 0.96 0.04 
Controls 30 1.00 0.00 0.00 60 1.00 0.00 
        
-449 C/G 
rs112362682 
C 
  CC CG GG 
1.00 
 C G 
1.00 
Patients 47 0.98 0.00 0.02 94 0.98 0.02 
Controls 30 0.97 0.03 0.00 60 0.98 0.02 
        
-399 T/G 
rs884409 
T 
  TT TG GG 
0.70 
 T G 
0.80 
Patients 47 0.85 0.04 0.11 94 0.87 0.13 
Controls 30 0.83 0.13 0.04 60 0.90 0.10 
        
-397 A/C 
This study 
NID 
  AA AC CC   A C  
Patients 47 0.72 0.28 0.00 
0.08 
94 0.86 0.14 
0.11 
Controls 30 0.90 0.10 0.00 60 0.95 0.05 
          
-238 A/G 
rs868106 
G 
  AA AG GG   A G  
Patients 47 0.04 0.26 0.70 
0.00 
94 0.17 0.83 
0.00 
Controls 29 0.38 0.17 0.45 58 0.47 0.53 
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Table 3.2 continued 
CYBRD1 (ENSG0000007196) 
Nucleotide position 
and change 
 Group n Genotype Frequency 
P-value 
(Genepop) 
2n Allele Frequency 
P-value 
(TFPGA) 
-166 C/G 
rs2356782 
C 
  CC CG GG   C G  
Patients 43 0.35 0.02 0.63 
0.00 
86 0.36 0.64 
0.00 
Controls 28 0.71 0.11 0.18 56 0.77 0.23 
          
            
            
            
HAMP (ENSG00000105697) 
Nucleotide position 
and change 
Ancestral allele 
(dbSNP) 
Group n Genotype Frequency 
P-value 
(Genepop) 
2n Allele Frequency 
P-value 
(TFPGA) 
-1631 C/T 
rs66868858 
C 
  CC CT TT 
0.70 
 C T 
0.71 
Patients 48 0.48 0.48 0.04 96 0.72 0.28 
Controls 27 0.52 0.33 0.15 54 0.69 0.31 
        
-582 A/G 
rs10421768 
G 
  AA AG GG 
0.67 
 A G 
0.83 
Patients 49 0.65 0.33 0.02 98 0.82 0.18 
Controls 29 0.72 0.24 0.04 58 0.84 0.16 
        
-323 C/T 
This study 
NID 
  CC CT TT 
1.00 
 C T 
1.00 
Patients 49 0.98 0.02 0.00 98 0.99 0.01 
Controls 29 1.00 0.00 0.00 58 1.00 0.00 
        
            
            
            
HFE (ENSG00000010704) 
Nucleotide position 
and change 
Ancestral allele 
(dbSNP) 
Group n Genotype Frequency 
P-value 
(Genepop) 
2n Allele Frequency 
P-value 
(TFPGA) 
-1168 A/G 
rs62625311 
A 
  AA AG GG 
0.50 
 A G 
0.51 
Patients 49 0.74 0.22 0.04 98 0.92 0.08 
Controls 28 0.68 0.25 0.07 56 0.96 0.04 
        
-561 A/G 
This study 
NID 
  AA AG GG   A G  
Patients 45 0.24 0.73 0.02 
0.00 
90 0.61 0.39 
0.02 
Controls 22 0.64 0.36 0.00 44 0.82 0.18 
          
-467 G/C 
rs2794720 
C 
  GG GA AA 
0.54 
 G A 
0.51 
Patients 49 0.84 0.16 0.00 98 0.85 0.15 
Controls 24 0.92 0.08 0.00 48 0.80 0.20 
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Table 3.2 continued 
SLC40A1 (ENSG00000138449) 
Nucleotide position 
and change 
Ancestral allele 
(dbSNP) 
Group n Genotype Frequency 
P-value 
(Genpop) 
2n Allele Frequency 
P-value 
(TFPGA) 
-1470 C/T 
rs16831699 
G 
  CC CT TT 
0.43 
 C T 
0.68 
Patients 49 0.88 0.12 0.00 98 0.94 0.06 
Controls 21 0.95 0.05 0.00 42 0.98 0.02 
        
-1461 T/C 
rs77227487 
T 
  TT TC CC 
0.54 
 T C 
0.44 
Patients 49 0.71 0.21 0.08 98 0.82 0.18 
Controls 21 0.86 0.05 0.09 42 0.88 0.12 
        
-1399 G/A 
rs79516140 
C 
  GG GA AA 
0.27 
 G A 
0.08 
Patients 49 0.94 0.02 0.04 98 0.95 0.05 
Controls 21 0.86 0.00 0.14 42 0.86 0.14 
        
-1355 G/C 
rs3811621 
C 
  GG GC CC 
0.18 
 G C 
0.21 
Patients 49 0.18 0.59 0.23 98 0.48 0.52 
Controls 21 0.14 0.43 0.43 42 0.36 0.64 
        
-1098 G/A 
rs10202029 
T 
  GG GA AA   G A  
Patients 49 0.51 0.45 0.04 
0.06 
98 0.73 0.27 
0.08 
Controls 21 0.76 0.24 0.00 42 0.88 0.12 
          
Abbreviations: 2n = number of alleles; A = adenine; C = cytosine; CYBRD1 = cytochrome B reductase 1 gene; del = deletion; G = guanine; HAMP = hepcidin antimicrobial 
protein gene; HFE = haemochromatosis protein; n = number of individuals; NID = SNP not found in dbSNP database; P = probability; rs = reference sequence; SLC40A1 = 
solute carrier family 40 member A1 gene; T = thymine 
 
Key to Table 3.2 
Blue  No homozygous individuals identified Green Only wild type individuals identified for the variant 
Orange Marginal statistical significance Pink No heterozygote individuals identified for the variant 
Red Statistically significant difference (P <0.05) Yellow Novel variant identified in this study 
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3.4.2 In Silico Analysis 
In silico analyses were performed to ascertain whether any putative TFBSs are created or 
abolished (Table 3.3). 
 
Table 3.3 Putative TFBSs predicted to be created or abolished by the presence of the 
variants 
Gene Variant 
Programs 
ALIBABA2 PROMO TFBlast 
Created Abolished Created Abolished Created Abolished 
CYBRD1 
- 1849 T/G - - - - - - 
- 1844 C/G GATA-1 - - GR-alpha - - 
-1813 C/T - SP1 p53, LEF-1 RXR-alpha - - 
-1749 del(T)6G - HNF-3, Hb - - - - 
- 1477 G/A - E1 
HNF-4alpha, 
C/EPBbeta 
MEF-2A, 
HNF-4alpha 
- - 
- 1459 T/C - c-Myc, SP1 
Pax-5, p53, 
HNF-1A 
HNF-1A, PR 
B 
- - 
- 1346 T/C - - - - - - 
- 1272 T/C NF-1 PR - c-Myb - - 
- 238 A/G NF-1 CTF - 
GR-beta, 
C/EBPbeta, 
C/EBPalpha, 
XBP-1 
OTX2 - 
- 166 C/G SP1, ETF 
Krox-20, 
CACCC-bi 
E2F-1 
NF-1, 
NFI/CTF 
- - 
        
HFE -561 A/G - - 
TFII-I, Pax-5, 
p53, E2F-1 
- - - 
Abbreviations: A = adenine; C = cytosine; CACCC-bi = CACCC-binding; C/EBP = CCAAT/enhancer binding 
protein; c-Myb = cellular myeloblastosis transcription factor; c-Myc = cellular myelocytomatosis transcription 
factor; CYBRD1 = cytochrome B reductase 1 gene; E1 = enhancer 1; E2F-1 = E2 promoter binding factor 1; 
ETF = embryonic TEA domain-containing factor; G = guanine; GR = glucocorticoid receptor; Hb = Hunchback; 
HFE = haemochromatosis protein; HNF = hepatocyte nuclear factor; Knox-20 = knotted1-like homeobox 20; 
LEF-1 = lymphoid enhancer-binding factor 1; MEF-2A = myocyte enhancer factor 2A; NF-1 = nuclear factor 1; 
NFI/CTF = nuclear factor 1/ CCAAT-binding transcription factor; OTX2 = orthodenticle homolog 2; Pax-5 = 
paired box 5; PR = progesterone receptor; RXR-alpha = retinoid X-receptor alpha; SP1 = specificity protein 1; T 
= thymine; TFII-I = transcription factor II-I ; XBP-1 = x-box binding protein 1 
 
A total of 41 sites were identified between the three programs used, of which 18 putative 
TFBSs were created and 23 were abolished. None of the programs used are in agreement for 
the majority of the statistically significant variants examined. The exceptions to this are the 
variants -1849 T/G and -1346 T/C both located in the promoter region of CYBRD1 as they 
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were both shown to have no effect on the original position and orientation of any existing 
TFBSs. 
3.4.3 Iron Parameter Analysis 
3.4.3.1 Descriptive Statistics 
Table 3.4 shows the descriptive statistics obtained for the iron parameter levels in the patient 
and control groups. 
 
Table 3.4 Descriptive statistics for iron parameter levels compared between patient and 
control groups 
Iron parameter 
Patient group Control group 
Untransformed data Transformed data Untransformed data Transformed data 
Serum ferritin 
Mean: 213.31 Mean: 4.75 Mean: 99.66 Mean: 4.45 
Median: 129 Median: 4.86 Median: 80.7 Median: 4.39 
Mode: 34 Mode: 3.53 Mode: 51.4 Mode: 3.94 
S.D.: 284.20 S.D.: 1.16 S.D.: 59.06 S.D.: 0.57 
Range: 1642 Range: 5.33 Range: 219.2 Range: 2.40 
Min: 8 Min: 2.08 Min: 22 Min: 3.09 
Max: 1650 Max: 7.41 Max: 241.2 Max: 5.49 
     
Serum iron 
Mean: 13.92 Mean: 2.30 Mean: 12.63 Mean: 2.37 
Median: 10.9 Median: 2.39 Median: 12.9 Median: 2.56 
Mode: 8.4 Mode: 2.13 Mode: 17 Mode: 2.83 
S.D.: 11.96 S.D.: 0.87 S.D.: 5.31 S.D.: 0.79 
Range: 65.1 Range: 3.79 Range: 24.9 Range: 4.43 
Min: 1.5 Min: 0.41 Min: 0.3 Min: -1.20 
Max: 66.6 Max: 4.20 Max: 25.2 Max: 3.23 
     
Serum transferrin 
Mean: 2.37  Mean: 2.03  
Median: 2.44  Median: 2.11  
Mode: 1.67  Mode: 0.91  
S.D.: 0.61  S.D.: 0.57  
Range: 2.58  Range: 2.09  
Min: 1.1  Min: 0.91  
Max: 3.68  Max: 3  
     
Transferrin saturation 
Mean: 25.58 Mean: 2.96 Mean: 26.14 Mean: 3.09 
Median: 20.3 Median: 3.01 Median: 24 Median: 3.18 
Mode: 30 Mode: 3.40 Mode: 24 Mode: 3.18 
S.D.: 21.41 S.D.: 0.77 S.D.: 14.45 S.D.: 0.70 
Range: 107.4 Range: 3.32 Range: 71.88 Range: 4.02 
Min: 4 Min: 1.39 Min: 1.32 Min: 0.27 
Max: 111.4 Max: 4.71 Max: 73.20 Max: 4.29 
Abbreviations: Max = maximum; Min = minimum; S.D. = standard deviation 
 
A large S.D. is observed for untransformed data in serum ferritin, serum iron and transferrin 
saturation. For these parameters the mean and median differ greatly which is a sign of 
potential non-normal distribution. After transformation the S.D. is dramatically decreased and 
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the mean and median for each transformed parameter is similar. Serum transferrin does not 
show the same pattern. 
 
3.4.3.2 Pearson r Correlation 
The Pearson r correlation was performed using GraphPad Prism™ (version 5.0.1) (GraphPad 
Software, San Diego, CA) (www.graphpad.com) to determine whether any correlations exist 
between iron parameters measured, including serum ferritin, serum iron, serum transferrin 
and transferrin saturation. These correlations were performed between iron parameters within 
the entire cohort as well as within the patient and control groups separately. Only analyses 
demonstrating statistically significant correlations are shown. Figure 3.1 shows a strong 
positive correlation between serum iron and transferrin saturation levels for the entire cohort. 
This relationship is mimicked in both the patient and control groups, shown in Figures 3.2 
and 3.3 respectively, although the relationship is weaker in the control group. 
 
 
Figure 3.1 Graph depicting the strong positive correlation between serum iron and 
transferrin saturation levels for the entire cohort 
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Figure 3.2 Graph depicting the strong positive correlation between serum iron and 
transferrin saturation levels in the patient group 
 
 
Figure 3.3 Graph depicting the strong positive correlation between serum iron and 
transferrin saturation levels in the control group 
 
Further analyses showed a weak negative correlation between serum transferrin and serum 
ferritin levels only in the patient group (Figure 3.4). 
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Figure 3.4 Graph depicting the negative correlation between serum ferritin and serum 
transferrin in the patient group 
 
No other combinations of iron parameter comparisons yielded statistically significant results. 
 
3.4.3.3 Normality Distribution and Data Transformation 
The untransformed patient group iron parameter data for serum ferritin, serum iron and 
transferrin saturation were non-normally distributed and the natural logarithm function was 
used to transform the data. Following data transformation it was found that the patient 
group‟s iron parameters were normally distributed. The data for serum transferrin was found 
to be normally distributed for both the patient and control groups. The remaining control 
group iron parameter data (for serum ferritin, serum iron and transferrin saturation) were also 
transformed but were found to be non-normally distributed regardless of transformation. This 
resulted in a non-parametric test being used to compare the data of the patient group to that of 
the control group for these iron parameters. 
In order to determine if a variant had any effect on iron parameters, the data was split into 
two groups for each variant (this was only performed for variants that had iron parameter data 
available). The first group was the “variant absent” group (composed of only wild type 
individuals) while the second group was the “variant present” group (composed of 
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individuals both heterozygous and homozygous for the variant). In this manner the groups 
were compared to one another for each variant to determine whether an overall effect could 
be seen for each iron parameter. For every redistribution of the data for each new variant 
being investigated, it was determined whether the data were normally distributed and 
depending on the result either a parametric (normally distributed data) or a non-parametric 
(non-normally distributed data) were used to compare the two groups 
 
3.4.3.4 T-tests (Parametric and Non-parametric) 
Figures 3.5-3.8 represent the results obtained when comparing the iron parameters of the 
patient to the control group as well as the results of the tests determining the influence of a 
particular variant on each of the iron parameters. All genotyped variants with iron parameter 
data available were tested. Only graphs for variants with statistically significant results have 
been shown (graphs for the other variants tested can be seen in Addendum C) 
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Figure 3.5 Comparison of iron parameters between the patient and control groups 
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It was determined that only serum transferrin was statistically significantly different (P < 
0.05) between the patient and control groups (Figure 3.5). Although the remaining iron 
parameters are not significantly different, differences can still be observed in the mean values 
between the patient and control groups. 
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Figure 3.6 Comparison of iron parameters to determine the effect of the variant -1470 
C/T in the promoter region of SLC40A1 
 
The variant -1470 C/T situated in the promoter region of SLC40A1 showed statistically 
significant differences (P < 0.05) in both serum ferritin and serum transferrin when 
comparing the variant absent to the variant present group (Figure 3.6). Although visible 
differences could be observed in both serum iron and transferrin saturation when comparing 
the two groups, these differences demonstrated no statistical significance. 
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Figure 3.7 Comparison of iron parameters to determine the effect of the variant -1355 
G/C in the promoter region of SLC40A1 
 
The variant -1355 G/C showed no statistically significant differences in serum iron, serum 
transferrin or transferrin saturation when comparing the variant-containing to the non-variant-
containing groups but did demonstrate a statistically significant difference when comparing 
serum ferritin for the two groups (P < 0.05) [Figure 3.7]. 
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Figure 3.8 Comparison of iron parameters to determine the effect of the variant -1098 
G/A in the promoter region of SLC40A1 
 
The last variant to be investigated for differences in iron parameters between individuals 
either wild type for the variant or carrying the variant (heterozygotes as well as homozygotes) 
was -1098 G/A located in the promoter region of the SLC40A1 gene (Figure 3.8). While 
serum ferritin, serum iron and transferrin saturation showed differences between the two 
groups, these differences exhibited no statistical significance. Serum transferrin however 
demonstrated strong statistical significance (P < 0.01) when comparing the variant absent and 
variant present groups. 
Bonferroni correction was performed where a P-value of less than 0.0017 was required to 
remain statistically significant. All previously statistically significant results do not stand up 
to this correction but it is important to note that the Bonferroni correction is one of the most 
stringent tests to deter the finding of false positives and thus the results should not be 
dismissed outright (Hochberg & Benjamini, 1990). 
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3.5 DISCUSSION 
An assortment of techniques was employed in this study in order to determine whether any 
variation exists in the promoter region of 5 genes – CYBRD1, HAMP, HFE, LTF and 
SLC40A1 – implicated in iron metabolism. Initially, a small subset of samples was subjected 
to semi-automated bi-directional sequencing analysis and this yielded a total of 40 variants 
identified in the promoter region of the genes under investigation. Ten novel variants were 
identified in the current study and 30 variants proved to be previously identified (dbSNP 
database). 
The remaining samples of the cohort were genotyped for these variants using either HEX-
SSCP analysis, RFLP analysis where possible, or, in cases where the variants were too 
closely spaced for the other analysis techniques, semi-automated bi-directional sequencing 
analysis was used. Once genotyping was complete, the data was analysed using Fisher‟s 
exact test or the chi-squared test (as described in section 2.6.2) in TFPGA, which tested for 
departure from HWE (Table 3.1). The LTF promoter region variants proved difficult to 
genotype and were subsequently omitted from further analyses. It should be noted that only 
homozygous individuals were observed for the variant -457 T/C in both the patient and 
control groups, which may indicate a different ancestral allele for this population group. 
The program TFPGA was also utilised to calculate the genotype and allele frequencies and 
was used to perform the Exact test, which is used to determine whether the patient and 
controls groups have statistically significant differences in allele frequencies (Table 3.2). The 
Exact test performs an algorithm with a set number of replications. The replications of the 
test reduce the number of false positives obtained through familywise error rate and so it is 
unnecessary to use a correction method such as the Bonferroni correction (Moran, 2003; 
Nakagawa, 2004). TFPGA only performs the Exact test when comparing allelic population 
differentiation; for this reason the program Genepop was used to examine genotypic 
population differentiation. The default settings for both programs were used (Table 3.5). 
 
Table 3.5 Default settings for the Exact test used in TFPGA and Genepop 
 TFPGA Genepop 
Number of dememorization steps 1 000 10 000 
Number of batches 10 100 
Number of permutation/ iterations 2 000 5 000 
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Following mutation detection, in silico analyses were performed in order to ascertain whether 
any putative TFBSs were abolished or created due to the presence of a variant (Table 3.3). 
The predicted implications of these TFBSs and their transcription factors were investigated. 
Finally, the iron parameter data were investigated to determine whether any of the variants 
had an effect on the parameter levels. This was ascertained by performing unpaired t-tests to 
compare groupings of data. The data were grouped for each variant based on whether the 
variant was present or absent, i.e., there was a „variant present‟ group and a „variant absent‟ 
group. The „variant present‟ group consisted of individuals that are either heterozygous or 
homozygous for the variant, while the „variant absent‟ group consisted of only wild type 
individuals. This test was used to determine whether a statistically significant difference 
occurred between the two groups based on the presence of each variant (Figures 3.5 to 3.8). 
Of the 31 loci tested, 18 showed departure from HWE. Genotyping errors and small sample 
size may inflate the occurrence of type 1 errors when assessing HWE but other factors may 
also play a role (Li & Li, 2008). When selecting individuals for a genetic study from a 
specific group in the population (in this case from a TB patient group), one is no longer 
sampling randomly and an over-representation occurs of these individuals when compared to 
the whole population. This non-random sampling may be one of the reasons for departure 
from HWE. Other documented reasons for departure from the model may include: migration, 
mutation, selection, the presence of a rare allele, undetected deleted alleles in heterozygotes, 
inbreeding and admixture of the population (Schaid et al., 2006). It is possible that one or 
more of these factors, such as selection or the presence of rare alleles, are influencing the 
study cohort, which could also account for the deviation of so many loci from HWE. 
The deviation of so many loci from HWE, while troubling, is most likely due to the small 
sample size of the study population and so future studies should correct for this. However, it 
is important to note that linkage disequilibrium (LD) may cause deviation from HWE as it 
affects the random assortment of alleles, thereby influencing the allele frequencies of the 
linked loci (Feder et al., 1996: Nielsen et al., 1999). Feder et al. (1996) go on to explain that 
it may even be possible to identify disease-associated loci by their departure from HWE, thus 
it should not be surprising to find that some of the variants identified in this study are found 
to be in Hardy-Weinberg disequilibrium (HWD) within the patients groups. Feder et al. 
(1996) noted that alleles at these loci appear to have an excess of homozygosity, which is 
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mimicked in some of the current study‟s data, which could partly explain the large number of 
loci that deviate from HWE. 
Goudet et al. (1996a) suggest the use of an Exact test for genotypic population differentiation 
as it does not assume HWE for the loci tested; the test assumes random sampling of 
genotypes rather than alleles. For this reason Genepop was used since it performs this test, 
thus more emphasis is placed on the genotype differences between the patient and control 
group than on the allele differences (as the TFPGA equivalent test assumes HWE for the 
allele). 
The Pearson r correlation was performed to determine if any of the iron parameters shared a 
relationship or showed reliance on one another. This was performed for the entire cohort‟s 
iron parameter data as well as for the patient and control groups separately, to determine if 
disease status affected these relationships. A relationship was discovered to exist between 
serum iron and transferrin saturation and this was visible in the entire cohort as well as within 
the patient and control groups (Figures 3.1 to 3.3). Since iron has the potential to be toxic 
when unbound, binding of it to transferrin is encouraged to the point where virtually no 
unbound iron is found in the bloodstream (Halliwell & Gutteridge, 1984; Ong et al., 2006). 
The relationship between serum iron and transferrin saturation is such that when the level of 
iron in the bloodstream increases the potential for instability and free radical formation 
increases, which leads to more iron becoming transferrin-bound and therefore more 
transferrin will become saturated. It was observed that the relationship is much stronger in the 
patient group than in the control group. The Pearson r value in the patient group was 0.9722 
(i.e., 97% dependence between the two parameters) in comparison with the control group that 
had a Pearson r value of 0.7549 (only 75% dependence). This may be explained by the 
body‟s innate ability to compete for iron with invading pathogens (Ong et al., 2006). The 
infection of M. tuberculosis could have caused the system to react by binding as much iron as 
possible in order to minimise iron availability for the pathogen. 
Interestingly, a relationship exists between serum ferritin and serum transferrin in the patient 
group alone (Figure 3.4). Although the relationship is not as strong as that of serum iron and 
transferrin saturation, it is still considered statistically significant as it has a Pearson r value 
of more than 0.6 (Pearson r = 0.6105). This could be an adaptive response by the body to 
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reduce iron availability for the pathogen by producing excess ferritin and transferrin in 
response to infection and inflammation, thereby decreasing the amount of unbound iron (Tran 
et al., 1997). 
Unpaired t-tests were performed to determine whether there is a statistically significant 
difference in the iron parameter levels when comparing the patient group to the control 
group. Although differences were observed between the groups for each parameter, only 
serum transferrin proved to be statistically significantly different (P < 0.05). The patient 
group had a higher mean value for this iron parameter than the control group. These results 
and the results of the Pearson‟s r correlation analysis may indicate an adaptive response of 
the host to pathogenic infection in an attempt to limit iron availability (Ong et al., 2006). 
Therefore it is not surprising that the patient group has higher levels of serum transferrin, 
probably in response to the original infection. 
The HAMP, HFE and SLC40A1 promoter region variants were investigated for their effect on 
the iron parameters serum ferritin, serum iron, serum transferrin, and transferrin saturation. 
No statistically significant results were found for either the HAMP or the HFE promoter 
variants, suggesting that these variants do not influence the levels of these iron parameters. 
The HAMP promoter variant -323 C/T was not tested in this manner as only one individual 
was found to be heterozygous while the remaining individuals in the cohort were wild type. 
Three of the SLC40A1 promoter variants yielded statistically significant results when 
determining the influence of a variant on iron parameters (Figures 3.6-3.8). 
The variant -1470 C/T was found to be statistically significantly different (P < 0.05) when 
comparing the variant absent group to the variant present group for the iron parameters serum 
ferritin and serum transferrin. The median value of serum ferritin in the variant absent group 
(Figure 3.6) was higher than that of the variant present group. Conversely, serum transferrin 
was, on average, higher in the variant present group than that of the variant absent group. 
This would indicate that the variant might be involved with the decreased accumulation of 
serum ferritin and the increased accumulation of serum transferrin. This variant occurs in the 
promoter region of the SLC40A1 gene and as such may influence the export of iron from 
cells. From the iron parameter data it can be expected that this variant could cause the 
increased expression of SLC40A1 which in turn would lead to increased iron accumulation in 
the blood stream and thus increased transferrin accumulation and decreased ferritin 
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accumulation. Future studies should investigate the effect of this variant on gene expression 
in order to corroborate this. Interestingly, this variant seems to be related to the increased 
accumulation of transferrin and decreased accumulation of ferritin which would suggest that 
transferrin is being used as the primary mechanism to bind iron. This could provide the ideal 
environment for M. tuberculosis proliferation as the bacterium more readily outcompetes 
transferrin for iron than it does ferritin (Gobin & Horwitz, 1996). 
The variants -1355 G/C and -1098 G/A both, on average, had higher levels of serum ferritin 
and serum transferrin respectively in the variant present group (Figures 3.7 and 3.8). Both 
variants therefore play some role in the accumulation of these proteins. As described for the 
variant -1470 C/T, the increased accumulation of transferrin may create an advantageous 
environment for M. tuberculosis proliferation. However, the increased accumulation of 
ferritin related to these variants may be attributed to an adaptive response to bind iron to 
ferritin in order to decrease iron availability to the pathogen. 
The exact mechanism by which these three SLC40A1 promoter variants (-1470 C/T; -1355 
G/C, -1098 G/A) affect iron parameter levels is unclear and requires further elucidation. 
Functional studies in combination with staining different bodily tissues for iron (liver, 
pancreas, macrophage etc.) may aid in the understanding of the influence these variants have 
on iron parameter levels. 
Although variants were identified in the promoter region of HAMP, LTF and SLC40A1, they 
were excluded from further analyses either due to the difficulty in genotyping or to the non-
significant results obtained from genotype and allele frequency comparisons between the 
patient and control groups. The following sections will deal with the results of the in silico 
analyses. 
3.4.1 CYBRD1 
Mutation detection analysis of the promoter region of the CYBRD1 gene revealed the 
presence of four novel (-849 C/G -492 A/G, -454 C/T and -397 A/C) and 16 previously 
described variants [-1849 T/G, -1844 C/G, -1813 C/T, -1749 del(T)6G, -1540 G/A, -1477 
G/A, -1459 T/C, -1346 T/C, -1272 T/C, -1011 T/A, -627 T/C, -624 G/A, -449 C/G, -399 T/G, 
-238 A/G and -166 C/G]. The control group used for comparison for this promoter region was 
derived from a previous study and, as such, no iron parameter data was available. For this 
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reason no determinations could be made pertaining to the influence of any of the CYBRD1 
promoter region variants on iron parameters. 
Nine of the 20 identified variants were shown to differ statistically significantly when 
comparing the genotype frequencies of the patient and control groups, and these variants 
were subjected to in silico analyses to determine if any TFBSs were created or disrupted by 
their presence (Table 3.3). The variants -1849 T/G and -1346 T/C were not predicted to 
create or abolish any TFBSs due to their presence or absence. 
The variant -1813 C/T was predicted to create a p53 and a LEF-1 TFBS but to abolish a SP1 
and a RXR-alpha TFBS. The transcription factor p53 has been shown to cause increased 
expression of genes to which it is linked, specifically during periods of infection (Weizer-
Stern et al., 2007). If this factor caused the increased expression of CYBRD1 it could lead to 
the enhanced absorption of iron, increasing the body‟s iron content, and could therefore 
potentially amplify an individual‟s susceptibility to TB infection. The lymphoid enhancer-
binding factor 1 (LEF-1) transcription factor has been connected to lymphocyte 
differentiation and, as yet, has not been seen to be expressed in any tissue other than 
lymphoid tissue (Travis et al., 1991). For this reason it is unlikely that this transcription factor 
is associated with the CYBRD1 gene, which is predominantly expressed in the gut. 
Specificity protein 1 (SP1) is a zinc finger transcription factor that binds to GC-rich regions 
of several promoters (Kaczynski et al., 2003). This transcription factor has been implicated in 
many processes such as cell growth, apoptosis, differentiation and immune responses. This 
factor can both repress and stimulate expression of target genes in response to physiological 
and pathological stimuli (Dhar et al., 2006). Its exact functioning when related to CYBRD1 
warrants further investigation because the presence of other variants in this gene is either 
predicted to create or abolish SP1 sites. 
The retinoid X-receptor alpha (RXR-alpha) transcription factor has been shown to form 
heterodimers with HNF-4alpha which exert their function by binding to DNA (Li et al., 
2000). RXR-alpha is part of the same steroid/thyroid nuclear receptor superfamily as HNF-
4alpha and, as such, is potentially involved in the same gene expression (Garcia et al., 1993). 
As HNF-4alpha has been implicated in TF expression it is possible that it, together with 
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RXR-alpha, is involved in the expression of other iron metabolism genes such as CYBRD1 
(Zakin, 1992). 
The CYBRD1 promoter variant -1749 del (T)6G caused the elimination of the transcription 
factors HNF-3 and Hb. The hepatocyte nuclear factor (HNF) transcription factors have been 
shown to be involved in liver development (Li et al., 2000). Zakin (1992) showed that HNF-
3α (a subgroup of HNF-3) acts as an enhancer for TF mRNA transcription in a liver cell line 
and this could indicate some function in CYBRD1. In fact, Collins and Hu (2007) showed that 
HNF-3 was among a group of transcription factors found to be enriched in a large-scale 
microarray-based study of intestinal gene expression during iron deprivation. Hunchback 
(Hb) is a transcription factor predominantly derived from the species Drosophila 
melanogaster and thus is not likely to play a role here (Berman et al., 2002). 
The presence of the promoter variant -1477 G/A predicted the creation of the TFBSs HNF-
4alpha and C/EBPbeta and elimination of the sites E1, HNF-4alpha, and MEF-2A. HNF-
4alpha is part of the HNF transcription factor family responsible for the regulation of liver 
development (Li et al., 2000). Zakin (1992) showed that HNF-4alpha acts as a transcription 
factor for the expression of TF. Binding of this factor to the promoter region of TF induced 
increased expression of this gene. From this it could be hypothesised that HNF-4alpha is 
involved in the expression of other iron genes such as CYBRD1. It is unlikely that this 
transcription factor played a role here, however, as it was shown to be both gained and lost 
due to the presence of the variant. The CCAAT/enhancer binding protein (C/EBP) 
transcription factor has been shown to interact with HNF-4alpha specifically in the promoter 
region of HAMP (Courselaud et al., 2002). Courselaud and colleagues (2002) explain that 
C/EBPalpha is a potent enhancer of HAMP expression while C/EBPbeta is a weak enhancer. 
The creation of a C/EBPbeta site might lead to a weak increase in the expression of CYBRD1. 
Very little information could be found regarding the E1 TFBS and any link it may have to 
any form of iron gene expression and so it is unlikely that this factor is associated with 
CYBRD1 expression. The monocyte-specific enhancer factor 2A (MEF-2A) transcription 
factor is a class of skeletal-specific factors which can indirectly either inhibit or increase the 
expression of certain skeletal genes (McGee & Hargreaves, 2004). Since this is a tissue-
specific transcription factor it is unlikely that it acts on the CYBRD1 gene as the necessary 
tissue environment is not present to direct the use of this factor. 
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The introduction of the variant -1459 T/C is predicted to produce the TFBSs Pax-5, p53, and 
HNF-1A and to abolish the sites for c-Myc, SP1, HNF-1A, and PR-B. Pax-5 is part of a 
family of highly conserved (in vertebrates) transcription factors that have a basic helix-loop-
helix structure and have the ability to bind E-box motifs in the promoter region of the 
transferrin (TF) gene within Sertoli cells, which subsequently increases TF expression (Wang 
et al., 2010; Chaudhary et al., 1997). With the exception of the research published by 
Chaudhary and colleagues (1997), little evidence exists to link Pax-5 to the regulation of 
genes involved in iron metabolism. As described for variant -1813 C/T, the introduction of a 
p53 TFBS could lead to the increased expression of CYBRD1. 
The c-Myc transcription factor contains basic helix-loop-helix and leucine zipper domains as 
well as a transactivation domain (Wu et al., 1999). This transcription factor functions by 
forming a heterodimer with a related protein, MAX, which has a similar structure. Wu and 
associates (1999) showed that c-Myc has the ability to both repress and stimulate the 
expression of FTH (the heavy subunit of ferritin) and IRP2 respectively, and so its precise 
influence on CYBRD1, if any, should be determined through functional analysis. 
The progesterone receptor B (PR-B) transcription factor is a hormone receptor that is part of 
the steroid superfamily. The PRs are generally involved in reproductive functions but have 
been shown to be expressed in other tissues such as the brain, liver, mammary glands, and 
spermatozoa (Lösel & Wehling, 2003; Gadkar-Sable et al., 2005). Hardy et al. (2008) 
demonstrated PR‟s ability to antagonise the inflammatory response pathway, which is known 
to cause the accumulation of iron. One could then suggest that if PR were truly acting in the 
promoter region of CYBRD1 then its abolishment could lead to accumulated iron. 
HNF-1A is another of the HNF family of transcription factors, the alpha and beta subtypes of 
which have been shown to influence the expression of genes localised exclusively in the 
small intestine within absorptive enterocytes (Wu et al., 1994). HNFs are generally thought to 
primarily influence the expression of genes in the liver but the evidence presented by Wu and 
colleagues (1994) indicates the possibility of HNF-1A to influence genes involved in dietary 
absorption. However, the results showed that HNF-1A was both lost and gained, so the 
overall effect of this variant in terms of HNF-1A is negligible. 
Stellenbosch University http://scholar.sun.ac.za
  Chapter 3: Results & Discussion 
 
75 
 
The variant -1272 T/C in the CYBRD1 promoter region was predicted to create a NF-1 TFBS 
and disrupt a PR and a c-Myb site. The nuclear factor 1 (NF-1) transcription factor is known 
for its involvement in the ras signal transduction pathway and has been associated with 
human cognitive development (Weeber & Sweatt, 2002). Little proof exists of a connection 
between NF-1 and iron metabolism and if this transcription factor does truly interact with 
CYBRD1 then this would merit further investigation into the method and reasons for 
interaction. The c-Myb transcription factor is employed in the hematopoietic system and 
gastrointestinal tract (Ramsay et al., 2003). This transcription factor has also been shown to 
play a critical role in the development of lymphocytes (Xiao et al., 2007). Whether this 
transcription factor influences the expression of CYBRD1 remains to be investigated and this 
is required before the actual importance of this site being abolished due to the presence of this 
variant can be established. 
The CYBRD1 promoter variant -238 A/G was predicted to create a NF-1 and a OTX2 TFBS 
and it was predicted to abolish the GR-beta, CTF, C/EBPalpha, C/EBPbeta and XBP-1 
TFBSs. The orthodenticle homolog 2 (OTX2) transcription factor is a member of the bicoid 
subfamily of proteins containing a homeodomain that plays a role in brain development 
(Lamonerie et al., 1996; Simeone, 1998). It is unclear if a connection exists between this 
transcription factor and CYBRD1 expression. The CCAAT-binding transcription factor (CTF) 
has been shown to be a transcriptional activator and influences the β-globin gene in vitro, 
among others (Jones et al., 1985). Whether a connection exists between CTF and CYBRD1 
expression is unclear and merits further investigation. 
Glucocorticoids are known to be integral in the basal and stress-related homeostasis of all 
higher organisms (Chrousos & Kino, 2005). They have been shown to influence 
approximately 20% of the human genome and their effects are demonstrated in almost every 
organ and tissue. The GR-alpha group of glucogorticoids have been described as complex, 
multifunctional domain proteins that operate in a ligand-dependent fashion when acting as 
transcription factors. Glucocorticoids have been implicated in the inhibition of inflammation 
and as such would inhibit the accumulation of iron within cells such as macrophages (Hentze 
et al., 2004; Rhen & Cidlowski, 2005). The GRs have been shown to influence the expression 
of several iron genes but have not yet been connected to the CYBRD1 gene. Despite this the 
possibility of such an interaction occurring is high since GRs are known to influence so much 
of the genome. 
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Unlike GR-alpha, GR-beta does not bind to GC-rich regions and despite being thought to be 
transcriptionally inactive it has been demonstrated to have the ability to influence GC-
mediated transcription (Oakley et al, 1996; Haarman et al., 2004). More specifically GR-beta 
can inhibit signal transduction by binding and subsequently inactivating GR-alpha. Since GR-
beta is transcriptionally inactive in the absence of GR-alpha, it can be postulated that this 
transcription factor will either have no effect on the expression of CYBRD1, or it will inhibit 
any GR-alpha present, which will cause the increased absorption of iron from the gut and 
possibly increase iron accumulation in macrophages (Hentze et al., 2004; Rhen & Cidlowski, 
2005). 
The transcription factor X-box binding protein 1 (XBP-1) consists of a basic leucine zipper 
(bZIP) domain and has been implicated in the regulation of MHC class II genes by binding to 
a promoter element referred to as an X-box (Yoshida et al., 2001). Some iron genes, such as 
HFE, bear structural similarities to the MHC-class proteins and so one could postulate that 
XBP-1 may interact with it but it would be a far leap to connect XBP-1 to CYBRD1 
expression. 
The CYBRD1 promoter variant -166 C/G was predicted to produce SP1, ETF, and E2F-1 
TFBSs but to disrupt Krox-20, CACCC-bi, NF-1, and NFI/CTF sites. The epidermal growth 
factor receptor (EGFR) has been recognised as an oncogene, which has been shown to be 
over-expressed in certain types of cancers (Kageyama et al., 1988). Furthermore, this gene 
seems to lack both a „TATA‟ box and a „CAAT‟ box but contains multiple GC boxes, which 
are recognised by the SP1 transcription factor. Evidence suggests that another transcription 
factor regulates the EGFR gene and this transcription factor was isolated and purified by 
Kageyama and colleagues (1988), who termed the factor EGFR-specific transcription factor 
(ETF). A study by Bem et al. (2009) on mechanical ventilation and inflammation in the lungs 
of pneumovirus infected mice found an enrichment of ETF, among other transcription 
factors. These results demonstrate that downstream proinflammatory pathways may be 
transcriptionally activated due to the interaction between mechanical ventilation and 
pathogens. This would indicate that ETF is involved in the proinflammatory response, which 
would indicate that its role in this pathway could lead to iron accumulation in the cells. Thus 
it could be hypothesised that the introduction of an ETF TFBS may increase an individual‟s 
susceptibility to TB infection since it could aid in the activation of an inflammatory response. 
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This variant was also predicted to create an E2F-1 TFBS. Although there appears to be no 
direct link between this transcription factor and iron metabolism, the factor has been 
identified as a key player in regulation of the cell cycle progression from the G1 phase to the 
S phase (Jamshidi-Parsian et al., 2005). It has also been identified for its role in apoptosis 
together with the transcription factor p53 (Wu & Levine, 1994). E2F-1 directly affects the 
expression of the transcription factor c-Myc, which is in involved in iron homeostasis, so it is 
possible that the presence of this transcription factor may indirectly affect genes involved in 
iron metabolism (Wu & Levine, 2005). 
The transcription factor Krox-20 (also known as early growth factor 2 or egr2) is a zinc finger 
protein that is rapidly activated in fibroblasts by growth factors (Chavrier et al., 1989; Bhat et 
al., 1992). Research has shown that Krox-20 has decreased expression in TF knockout mice 
indicating that the transcription factor interacts with this gene (Levy et al., 1999). This would 
signify a role for Krox-20 in the regulation of iron metabolism. Of specific relevance to the 
current study was the discovery of the enrichment for Krox in a microarray study on 
intestinal gene expression during iron deprivation by Collins and Hu (2007). This would link 
Krox transcription factors to CYBRD1 expression but the exact mechanism by which this 
occurs requires further investigation. 
The CACCC-binding factor (CACCC-bi) is part of a broad range of zinc finger transcription 
factors that bind „CACCC-boxes‟ in DNA, which leads to either activation or suppression of 
gene expression (van Vliet et al., 2000). Since these proteins share a similar binding sequence 
(CACCC) the program ALIBABA2 could not distinguish which CACCC-bi factor this was. 
This would need to be determined in order to assess the effect this factor has on CYBRD1 
expression, if any. The nuclear factor-I/CCAAT-binding transcription factor (NFI/CTF), 
which comes from a group of proteins that recognise and bind to the cellular DNA sequence 
GCCAAT, has been implicated in eukaryotic transcription (Uramoto et al., 2003). These 
transcription factors are known to play a role in the regulation of genes that are ubiquitously 
expressed as well as those that are influenced by hormones, developmental stages, and 
nutrition. As described for the variant -1272 T/C, these NF-1 family factors have the ability 
to both repress and stimulate transcription of genes and, as such, will require further 
investigation in order to determine their effect on CYBRD1 expression (Gronostajski, 2000). 
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3.4.2 HFE 
Through mutation detection analysis 4 variants were identified in the promoter region of 
HFE. Two novel SNPs (-561 A/G and -331 A/C) and 2 previously described SNPs were 
identified (-1168 A/G and -467 G/C). The -331 A/C variant proved difficult to genotype as no 
RE recognition sites were present and analysis on HEX-SSCP PAA gels proved impossible. 
It was then decided to exclude this variant from further analyses. 
Of the 3 remaining variants only -561 A/G yielded statistically significant results when 
comparing the patient and control groups for deviations in genotype and allele frequencies. 
The putative TFBS prediction program PROMO was the only program to predict changes to 
occur due to the presence of this variant. It predicted the creation of 4 TFBSs and their 
potential involvement in the regulation of the HFE gene was investigated. 
The first TFBS predicted to be created by the presence of the variant -561 A/G is 
transcription factor II-I (TFII-I). TFII-I is a ubiquitously expressed multifunctional 
transcription factor that is believed to link signal transduction processes to transcription (Roy, 
2001). This transcription factor is activated in reaction to extracellular signals. It has also 
been proposed that TFII-I can function as both a basal transcription factor and an activator. 
This would imply that TFII-I facilitates communication between the core promoter region 
and upstream activator sites. As a transcription factor it is known to upregulate expression of 
a gene in response to external stimuli. It is possible that the increased expression of HAMP 
could lead to increased macrophage iron concentrations, which would dissuade systemic 
pathogenic infection but would be ideal for mycobacterial infection of the macrophage (Sow 
et al., 2007). This would indicate the potential for this variant to increase an individual‟s 
susceptibility to TB. 
Paired box 5 (Pax-5) was the next TFBS predicted to be created in the presence of this 
variant. As described in section 3.4.1, its role in the regulation of TF may suggest that it is 
capable of regulating other genes involved in iron metabolism, such as HAMP, and, if so, 
may also implicate this variant in TB susceptibility since Pax-5 could potentially cause 
increased expression of hepcidin. 
The TFBS for p53 was also identified as a putative binding site created by the presence of the 
-561 A/G variant. This transcription factor has been directly linked to the regulation of 
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HAMP, particularly during times of inflammation and infection (Weizer-Stern et al., 2007). 
As described for TFII-I and Pax-5, the increased expression of HAMP could possibly cause 
increased susceptibility to TB. The last TFBS identified by PROMO to have been created by 
the presence of the -561 A/G variant is E2F-1. This transcription factor may affect iron gene 
regulation as described for CYBRD1 promoter variant -166 C/G. 
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4.1 CONCLUDING REMARKS AND FUTURE PROSPECTS 
The aim of this study was to elucidate the role of five genes involved in iron metabolism – 
CYBRD1, HAMP, HFE, LTF and SLC40A1 – in relation to M. tuberculosis susceptibility. The 
first objective identified in order to achieve this aim was to identify a suitable cohort 
consisting of TB patients and population-matched controls. A group comprising 49 TB 
patients was compared to a control group made up of a total of 51 healthy control individuals 
split into two subgroups for specific analyses. A limitation of this study was the small sample 
size of the cohort, but this was a pilot study and future work will include a larger cohort. The 
standard deviation for age between the two groups was significantly different and future work 
should aim to collect samples from individuals that are truly population-matched (for age and 
sex) or corrections for age and sex may be performed to minimise their influence on the data. 
The DNA samples from the control group were particularly difficult to amplify due to 
minimal quantity and age of the samples. Future researchers could corroborate the findings 
from this study and validate them through the use of a larger cohort. 
The second objective identified by this study was to identify and compare iron parameters 
(including serum ferritin, serum iron, serum transferrin and transferrin saturation) between 
the groups. It was determined that serum iron and transferrin saturation share a strong 
positive relationship and that this relationship is particularly notable in the patient group. This 
could suggest an influence on iron parameters by disease status and adaptive response to 
infection. This relationship could be explained as the body‟s response to competitively bind 
iron to limit its availability for invading pathogens (Ong et al., 2006). Interestingly, a 
relationship between serum ferritin and serum transferrin was exclusively observed in the 
patient group. This could be due to an adaptive response by the body in an attempt to limit 
free iron availability by producing excess ferritin (Tran et al., 1997). This relationship shows 
a decrease in transferrin as ferritin increases. This could also be explained as an adaptive 
response by the body to preferentially bind iron in ferritin rather than transferrin as M. 
tuberculosis can compete with TF and LTF for the binding of iron (Gobin & Horwitz, 1996). 
Therefore, it is beneficial to the system if most iron is bound in ferritin which the bacterium 
cannot access as easily. 
The third and fourth objectives recognised were to genotype all individuals for any identified 
novel and/or previously discovered variants in the promoter region of the 5 genes under 
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investigation, and to determine allele and genotype frequencies for comparison respectively. 
One of the limitations presented here is that the LTF gene could not be genotyped due to 
difficulties in amplifying the fragments and differentiating the different genotypes on HEX-
SSCP gels. In future this gene should be investigated as it is likely to play a role in M. 
tuberculosis susceptibility indicated by its direct interaction with the pathogen (Olakanmi et 
al., 2007). It is suggested that the promoter region of this gene be genotyped by semi-
automated bi-directional sequencing analysis to limit redundancies and genotyping difficulty. 
The genotyping of some other fragments did involve HEX-SSCP analysis which is a system 
with only 70-100% sensitivity which can be influenced by number a of factors such as 
temperature, DNA fragment size, gel composition, and the fluorescent stain used (Fujita & 
Silver, 1994; Bonner & Ballard, 1999). The variation for these variables was minimised 
where possible. Funding was limited for this project and it is advised that future research 
should utilise more sensitive genotyping methods such as RFLP or semi-automated bi-
directional sequencing analysis should more funding be available. Genotyping efficiency 
could also be increased as not all samples were genotyped for each variant (as indicated by 
the n values in Table 3.2). Many of the variants were found to deviate from HWE but this can 
most likely be attributed to the small sample size or to a true disease association for some of 
the variants (Schaid & Jacobsen, 1999). 
The genotype and allele frequencies were determined for the genotyped variants as shown in 
Table 3.2. The variants that were found to be statistically significant between the patient and 
control groups were : CYBRD1: -1849 T/G, -1813 C/T, -1749 del (T)6G, -1477 G/A, -1459 
T/C, -1346 T/C, -1272 T/C, -238 A/G and -166 C/G; HFE: -561 A/G. These variants were 
used to fulfil the fifth identified objective which was to perform in silico analyses to 
determine their effect on gene expression. 
The majority of the TFBSs predicted to be abolished or created in the presence or absence of 
the CYBRD1 promoter region variants could lead to the increased expression of the gene. If 
CYBRD1 expression is implicated in M. tuberculosis susceptibility then this result would be 
expected. The increase would lead to excess iron absorption and this, in turn, would cause the 
total iron levels within the body to rise. This could potentially increase an individual‟s risk 
for TB infection as the pathogen thrives in an iron rich host (Schaible & Kaufmann, 2004). 
This is coupled with the results from the HFE in silico analyses which also show a general 
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trend of TFBSs that could lead to the increase of gene expression. The increased activity of 
HFE would lead to the decreased ability of TF to transport iron into cells but would not affect 
LTF which mainly transports iron into macrophages and other white blood cells (Sánchez et 
al., 1992). This could potentially lead to the increased iron availability within macrophages 
which is advantageous for M. tuberculosis infection. 
The results of the in silico analyses are supported by gene expression studies performed in 
our laboratory (unpublished data). Increased expression of both CYBRD1 and HFE in the 
same TB cohort are currently observed. From these results it can be determined that more 
research is required as to the exact mechanism by which these genes, their protein products, 
and the variants identified play a role in M. tuberculosis susceptibility. It should be noted that 
haplotype analyses may be performed in future to determine the compound effect of variants 
on disease susceptibility. 
The results of this study suggest that a link may exist between variants in the promoter region 
of iron metabolism genes and M. tuberculosis susceptibility. This emphasises the need for 
further investigation into the complex relationship between iron metabolism and pathogenic 
infection. This research can possibly contribute to our understanding of the interactions that 
occur and the genetic factors at play when distinguishing individuals in terms of their 
susceptibility to this pathogen. Research such as this could assist in the discovery of 
alternative treatment methods – such as iron chelation therapy suggested by Cronje et al. in 
2005 – which could circumnavigate the need for drug treatments which have adverse drug 
reactions and create difficulty in terms of adherence and therefore the proliferation of 
multiple drug-resistant mycobacteria. 
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ADDENDUM A  
A.1 PROMOTER REGION SEQUENCES OF CYBRD1, HAMP, HFE, LTF AND 
SLC40A1 
The sequences of each promoter region were sourced from the Ensembl (www.ensembl.org) 
website. The region investigated for each gene is provided in Figures A.1 to A.5. Each figure 
contains the sequence investigated as well as the primers used (highlighted in various colours 
described in the key and in Tables 2.1 to 2.3), the primers‟ orientation, the Ensembl reference 
number (below the sequence title), the start site of transcription (the „ATG‟ site is emphasised 
in bold), and the variants identified (underlined, assigned a number in superscript, and 
identified in the key to the figure). Arrows below the primers indicate their orientation – 
arrows pointing left indicate forward primers while arrows pointing right indicate reverse 
primers. 
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Figure A.1 The promoter region investigated upstream of the CYBRD1 gene 
Key to Figure A.1: 
Primers Variants identified in the current study 
BP1 Sequence 
1 
-1849 T/G 
2 
-1844 C/G 
3 
-1813 C/G 
4 
-1749 del (T)6G 
BP2 Sequence 
5 
-1540 G/A 
6 
-1477 G/A 
7 
-1459 T/C 
8 
-1346 T/C 
 
9 
-1272 T/C 
10 
-1011 T/A 
11 
-849 C/G 
12 
-627 T/C 
 
13 
-624 G/A 
14 
-492 A/G 
15 
-454 C/T 
16 
-449 C/G 
 
17 
-399 T/G 
18 
-397 A/C 
19 
-238 A/G 
20 
-166 C/G 
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Figure A.2 The promoter region investigated upstream of the HAMP gene 
Key to Figure A.2: 
Primers Variants identified in the current study 
PP1 Sequence 
1 
-1631 C/T 
2 
-582 A/G 
3 
-323 C/T 
4 
-188 C/T 
PP2 Sequence 
PP1 (-1631 C/T) 
PP2 (-582 A/G) 
PP3 (-323 C/T) 
[PP4 (-188 C/T)] 
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Figure A.3 The promoter region investigated upstream of the HFE gene 
Key to Figure A.3: 
Primers Variants identified in the current study 
HP1 Sequence 
1 
-1168 A/G 
2 
-561 A/G 
3 
-467 G/C 
4 
-331 A/C 
HP2 Sequence 
HP1 (-1168 A/G) 
HP2 (-561 A/G) 
HP3 (-467 G/C) 
HP4 (-331 A/C) 
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Figure A.4 The promoter region investigated upstream of the LTF gene 
Key to Figure A.4: 
Primers Variants identified in the current study 
LP1 Sequence 
1 
-1377 T/G 
2 
-746 del AAA/ins AA 
3 
-457 T/C  
4 
-437 C/G 
LP2 Sequence 
LP1 (-1377 T/G) 
LP2 (-746 del AAA/ins AA) 
LP3 (-457 T/C) 
LP4 (-437 C/G) 
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Figure A.5 The promoter region investigated upstream of the SLC40A1 gene 
Key to Figure A.5: 
Primers Variants identified in the current study 
SP1 Sequence 
1 
-1470 C/T 
2 
-1461 T/C 
3 –1399 G/A 4 -1355 G/C 
SP2 Sequence 
5 
-1098 G/A 
6 –750 G/A 7 -662 C/T 8 -501 T/C 
SP3 Sequence (5 variants) 
SP1 (-750 G/A) 
SP2 (-662 C/T) 
SP3 (-501 T/C) 
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ADDENDUM B  
B.1 VARIANT IDENTIFICATION 
B.1.1 Chromatograms 
Chromatograms were obtained from the Central Analytical Facility (CAF) from sequence 
reactions on PCR amplified samples using primers as indicated in Tables 2.1 to 2.3. All 
variants were identified in the initial screened group and chromatograms are provided. The 
titles of the variants that were excluded from further analyses are highlight in red. Horizontal 
arrows represent the point at which the base pair change occurs for the assigned variant. 
 
CYBRD1 variants 
-1849 T/G 
Wild type (TT) Heterozygote (TG) Homozygote (GG) 
   
-1844 C/G 
Wild type (CC) Heterozygote (CG) Homozygote (GG) 
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-1813 C/T 
Wild type (CC) Heterozygote (CT) Homozygote (TT) 
  
 
-1749 del (T)6G 
Wild type 
 
Heterozygote (-/del) 
 
Homozygote (del/del) 
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-1540 G/A 
Wild type (GG) Heterozygote (GA) Homozygote (AA) 
   
-1477 G/A 
Wild type (GG) Heterozygote (GA) Homozygote (AA) 
  
 
-1459 T/C 
Wild type (TT) Heterozygote (TC) Homozygote (CC) 
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-1346 T/C 
Wild type (TT) Heterozygote (TC) Homozygote (CC) 
   
-1272 T/C 
Wild type (TT) Heterozygote (TC) Homozygote (CC) 
 
  
-1011 T/A 
Wild type (TT) Heterozygote (TA) Homozygote (AA) 
 
 
 
-849 C/G 
Wild type (CC) Heterozygote (CG) Homozygote (GG) 
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-627 T/C 
Wild type (TT) Heterozygote (TC) Homozygote (CC) 
 
 
 
-624 G/A 
Wild type (GG) Heterozygote (GA) Homozygote (AA) 
 
  
-492 A/G 
Wild type (AA) Heterozygote (AG) Homozygote (GG) 
   
-454 C/T 
Wild type (CC) Heterozygote (CT) Homozygote (TT) 
 
No heterozygotes 
observed in initial 
screening  
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-449 C/G 
Wild type (CC) Heterozygote (CG) Homozygote (GG) 
 
  
-399 T/G 
Wild type (TT) Heterozygote (TG) Homozygote (GG) 
 
  
-397 A/C 
Wild type (AA) Heterozygote (AC) Homozygote (CC) 
 
 
No homozygotes 
observed in initial 
screening 
-238 A/G 
Wild type (AA) Heterozygote (AG) Homozygote (GG) 
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-166 C/G 
Wild type (CC) Heterozygote (CG) Homozygote (GG) 
 
 
 
HAMP variants 
-1631 C/T 
Wild type (CC) Heterozygote (CT) Homozygote (TT) 
   
-582 A/G 
Wild type (AA) Heterozygote (AG) Homozygote (GG) 
  
No homozygotes 
observed in initial 
screening 
-323 C/T 
Wild type (CC) Heterozygote (CT) Homozygote (TT) 
  
No homozygotes 
observed in initial 
screening 
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-188 C/T 
Wild type (CC) Heterozygote (CT) Homozygote (TT) 
 
 
No homozygotes 
observed in initial 
screening 
HFE variants 
-1168 A/G 
Wild type (AA) Heterozygote (AG) Homozygote (GG) 
  
No homozygotes 
observed 
-561 A/G 
Wild type (AA) Heterozygote (AG) Homozygote (GG) 
  
 
-467 G/C 
Wild type (GG) Heterozygote (GC) Homozygote (CC) 
 
No heterozygotes 
observed in initial 
screening 
 
  
Stellenbosch University http://scholar.sun.ac.za
  Addendum B 
 
118 
 
-331 A/C 
Wild type (AA) Heterozygote (AC) Homozygote (CC) 
  
No homozygotes 
observed in initial 
screening 
LTF variants 
-1377 T/G 
Wild type (TT) Heterozygote (TG) Homozygote (GG) 
No wild type 
individuals observed 
 
 
-746 delAAA/ 
insAA 
(WT/-AAA) 11 and 14 adenines in sequence 
 
(WT/[-AAA/insAA]) 13 and 14 adenines in sequence 
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-746 delAAA/ 
insAA 
(continued) 
(-AAA/[-AAA/insAA]) 11 and 13 adenines in sequence 
 
(-AAA/-AAA) 11 adenines in sequence 
 
-457 T/C 
Wild type (TT) Heterozygote (TC) Homozygote (CC) 
No wild types 
observed 
No heterozygotes 
observed 
 
-437 C/G 
Wild type (CC) Heterozygote (CG) Homozygote (GG) 
  
No homozygotes 
observed 
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SLC40A1 variants 
-1470 C/T 
Wild type (CC) Heterozygote (CT) Homozygote (TT) 
 
 
No homozygotes 
observed 
-1461 T/C 
Wild type (TT) Heterozygote (TC) Homozygote (CC) 
   
-1399 G/A 
Wild type (GG) Heterozygote (GA) Homozygote (AA) 
   
-1355 G/C 
Wild type (GG) Heterozygote (GC) Homozygote (CC) 
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-1098 G/A 
Wild type (GG) Heterozygote (GA) Homozygote (AA) 
   
-750 G/A 
Wild type (GG) Heterozygote (GA) Homozygote (AA) 
  
No homozygotes 
observed in initial 
screening 
-662 C/T 
Wild type (CC) Heterozygote (CT) Homozygote (TT) 
   
-501 T/C 
Wild type (TT) Heterozygote (TC) Homozygote (CC) 
No wild types 
observed 
No heterozygotes 
observed 
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B.1.2 RFLP Gel Images 
PCR product digestion was performed as described in section 2.3.2 and electrophoresed 
(section 2.2.3). Examples of results obtained are provided below. The horizontal arrow in the 
gel image of variant -561 A/G indicates the lower band which makes the individual a 
heterozygote (this band is light thus the arrow is added ad an aid). 
 
HAMP 
-582 A/G 
 
HFE 
-561 A/G 
 
-467 G/C 
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B.1.3 HEX-SSCP Gel Images 
The images here illustrate variants detected by HEX-SSCP analysis. Horizontal arrows 
indicate differences in banding patterns allowing one to distinguish between genotypes. 
 
HAMP 
-1631 C/T 
 
-323 C/T 
 
-188 C/T 
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HFE 
-1168 A/G 
 
LTF 
-457 T/C 
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ADDENDUM C  
C.1 T-TESTS FOR IRON PARAMETER LEVEL COMPARISONS 
Unpaired t-tests were performed to ascertain whether a statistically significant difference 
could be observed between iron parameter levels in WT individuals, and those with the 
variant. Figures C.1 to C.7 represent those results which showed differences due to the 
presence of the variant but did not yield statistically significant results 
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Figure C.1 Comparison of iron parameters to determine the effect of the variant -1631 
C/T in the promoter region of HAMP 
 
Differences in iron parameters were observed for the -1631 C/T variant located in the 
promoter region of the HAMP gene when comparing the „no variant‟ group to the „variant‟ 
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group but none of these differences proved to be statistically significant (ns – as depicted in 
Figure C.1). 
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Figure C.2 Comparison of iron parameters to determine the effect of the variant -582 
A/G in the promoter region of HAMP 
 
The variant -582 A/G located in the promoter region of HAMP showed visible differences in 
iron parameters between the variant-containing and non-variant-containing groups but these 
results proved to be non-significant (Figure C.2). The same results were found for the variant 
-1168 A/G located in the promoter region of the HFE gene (Figure C.3). 
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Figure C.3 Comparison of iron parameters to determine the effect of the variant -1168 
A/G in the promoter region of HFE 
 
These results were imitated for the two remaining variants investigated in this manner: 
variants -561 A/G and -467 G/C both located in the promoter region of the HFE gene 
(Figures C.4 and C.5). 
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Figure C.4 Comparison of iron parameters to determine the effect of the variant -561 
A/G in the promoter region of HFE 
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Figure C.5 Comparison of iron parameters to determine the effect of the variant -467 
G/C in the promoter region of HFE 
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No statistically significant differences were seen for any of the four iron parameters when 
comparing the variant absent group to the variant present group for either the variant -1461 
T/C or the variant -1399 G/A (Figures C.6 and C.7 respectively). 
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Figure C.6 Comparison of iron parameters to determine the effect of the variant -1461 
T/C in the promoter region of SLC40A1 
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Figure C.7 Comparison of iron parameters to determine the effect of the variant -1399 
G/A in the promoter region of SLC40A1 
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